记事本2020 personal page - To The Moon

记事本2020

记事本2020

No personal profile

971Follow

44Followers

0Topic

0Badge

2021-08-30

666

UBS: Give WuXi Biologics (02269) a "Buy" rating with a price target of HK$142

2021-08-30

666

Business two-wheel drive improved strategic layout, Jingneng Clean Energy (0579.HK) interim results steadily improved

2021-08-30

666

Sorry, the original content has been removed

2021-08-26

666

Morgan Stanley: Give WuXi Biologics an "overweight" rating, the target price rose 3.6% to HK$170

2021-08-25

666

Zhongtai Securities: Maintain the "Buy" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments

2021-08-23

666

[Moving stocks] WuXi Biologics (02269.HK) rose 3.13%

2021-03-06

666

Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%

2021-03-06

666

Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3550828792714737","uuid":"3550828792714737","gmtCreate":1587765570145,"gmtModify":1604808867541,"name":"记事本2020","pinyin":"jsb2020jishiben2020","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":44,"headSize":971,"tweetSize":115,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-4","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Tiger Star","description":"Join the tiger community for 2000 days","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.53%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":811218252,"gmtCreate":1630326149476,"gmtModify":1676530269198,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811218252","repostId":"2163012390","repostType":2,"repost":{"id":"2163012390","kind":"news","pubTimestamp":1630308776,"share":"https://ttm.financial/m/news/2163012390?lang=en_US&edition=fundamental","pubTime":"2021-08-30 15:32","market":"hk","language":"zh","title":"UBS: Give WuXi Biologics (02269) a \"Buy\" rating with a price target of HK$142","url":"https://stock-news.laohu8.com/highlight/detail?id=2163012390","media":"智通财经","summary":"智通财经APP获悉，瑞银发布研究报告称，予药明生物“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。","content":"<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/UBS\">UBS</a>Published a study report stating that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) with a \"Buy\" rating and a target price of HK$142, raised its 2021-23 earnings per share forecast by 26% to 38% to reflect stronger-than-expected pandemic and CMO-related projects, and raised its 2020-24 revenue forecast by 11% to reflect stronger-than-expected growth in COVID-19 projects and pharmaceutical manufacturing outsourcing (CMO) growth.</p><p>According to the report, according to the management, there will be at least four to five non-COVID-19-related CMOs before the end of 2022, which is estimated to drive the company's long-term profit growth. The management will maintain the 2021 guidance, and it is expected that the revenue and net profit will increase by 65% year-on-year. The bank believes that if the growth is not affected by supply shortage, the company is expected to outperform the guidance.</p><p>According to the bank, according to the management, there is no evidence that the U.S. government will restrict U.S. companies from using CDMO companies based in China. At the same time, 20% of WuXi customers have considered using the company's production capacity in Europe and the United States to reduce risks. Considering the nature of the company's CDMO services, if drugs are produced in Europe and the United States and shipped there, they will not be regarded as exported from China to the United States, which is believed to reduce the risk of unstable drug supply.</p><p></body></html></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS: Give WuXi Biologics (02269) a \"Buy\" rating with a price target of HK$142</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS: Give WuXi Biologics (02269) a \"Buy\" rating with a price target of HK$142\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-30 15:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/UBS\">UBS</a>Published a study report stating that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) with a \"Buy\" rating and a target price of HK$142, raised its 2021-23 earnings per share forecast by 26% to 38% to reflect stronger-than-expected pandemic and CMO-related projects, and raised its 2020-24 revenue forecast by 11% to reflect stronger-than-expected growth in COVID-19 projects and pharmaceutical manufacturing outsourcing (CMO) growth.</p><p>According to the report, according to the management, there will be at least four to five non-COVID-19-related CMOs before the end of 2022, which is estimated to drive the company's long-term profit growth. The management will maintain the 2021 guidance, and it is expected that the revenue and net profit will increase by 65% year-on-year. The bank believes that if the growth is not affected by supply shortage, the company is expected to outperform the guidance.</p><p>According to the bank, according to the management, there is no evidence that the U.S. government will restrict U.S. companies from using CDMO companies based in China. At the same time, 20% of WuXi customers have considered using the company's production capacity in Europe and the United States to reduce risks. Considering the nature of the company's CDMO services, if drugs are produced in Europe and the United States and shipped there, they will not be regarded as exported from China to the United States, which is believed to reduce the risk of unstable drug supply.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/549312.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"02269":"药明生物"},"source_url":"http://www.zhitongcaijing.com/content/detail/549312.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163012390","content_text":"智通财经APP获悉，瑞银发布研究报告称，予药明生物(02269)“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包(CMO)增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。该行表示，据管理层指，现时未有证据美国政府将限制美国企业使用以中国为基地的CDMO企业，同时有20%药明的客户已考虑使用公司于欧美的产能以减低风险，考虑公司CDMO服务性质，假如药物于欧美生产并运往当地，将不被视作由中国出口至美国，相信可减低药物供应不稳的风险。","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":2678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811103906,"gmtCreate":1630293590105,"gmtModify":1676530259718,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811103906","repostId":"2163702540","repostType":2,"repost":{"id":"2163702540","kind":"news","pubTimestamp":1630285168,"share":"https://ttm.financial/m/news/2163702540?lang=en_US&edition=fundamental","pubTime":"2021-08-30 08:59","market":"us","language":"zh","title":"Business two-wheel drive improved strategic layout, Jingneng Clean Energy (0579.HK) interim results steadily improved","url":"https://stock-news.laohu8.com/highlight/detail?id=2163702540","media":"格隆汇","summary":"总结来说，整个2021年上半年，京能清洁能源凭借其自身的软硬实力，充分发挥多元化的竞争优势，使得各个业务板块实现稳健增长。","content":"<p><html><body><span>On August 26, Hong Kong stocks<a href=\"https://laohu8.com/S/00579\">Jingneng Clean Energy</a>(0579.HK) announced its 2021 interim results report: achieved operating income of RMB9.340 billion, representing a year-on-year increase of 12.81%; Profit before tax was RMB1,884 million, representing a year-on-year increase of 13.90%; Profit attributable to ordinary shareholders of the Company was RMB1,488 million, representing a year-on-year increase of 14.90%; Basic and diluted earnings per share were RMB18.05 cents.</span></p><p>This is an excellent report card. In the fiercely competitive market environment, in the first half of this year, the year-on-year growth rate of revenue and net profit of Jingneng Clean Energy both achieved double-digit growth. It can be said that there is progress in \"stability\" and full momentum for progress.</p><p><b><font color=\"#ff0000\">Steady business growth and further consolidation of industry position</font></b></p><p>Through the semi-annual performance report released by Jingneng Clean Energy, it can be found that while the operating performance has grown steadily, it has performed well in many business dimensions and has been continuously optimized.</p><p><b>The installed capacity has steadily increased,</b>As of June 30, 2021, the total installed capacity of the Company was 11.215 million kilowatts, representing a year-on-year increase of 14%, of which, the newly installed capacity of the wind power business segment was 349,000 kilowatts, all of which came from self-built projects.</p><p><b>The power generation showed a large increase.</b>As of June 30, 2021, the total power generation of the Company's holding was 16.179 billion kWh, representing a year-on-year increase of 17.73%.</p><p>Among which, the power generation of gas-fired power generation and heating business segment increased by 8.08% year-on-year;<b>The power generation of wind power business segment increased by 44.43% year-on-year; The power generation of photovoltaic power generation business segment increased by 37.87% year-on-year, significantly higher than the national industry level in the same period.</b></p><p><b>In summary,</b>Throughout the first half of 2021, Jingneng Clean Energy leveraged on its own soft and hard strengths and fully leveraged its diversified competitive advantages to achieve steady growth in various business segments.</p><p>In particular, the photovoltaic sector has exceeded the national level in the same period, fully catering to the development concepts of \"30,60\" and \"carbon peak and carbon neutrality\", further consolidating the company's industry leading position as a local new energy state-owned enterprise.</p><p><b><font color=\"#ff0000\">2. Independent development and project mergers and acquisitions are driven by two wheels, and the business synergy is highlighted</font></b></p><p>When judging the growth of an enterprise, there are often two points worth paying attention to. First, the growth of endogenous power depends on the accumulation of the enterprise itself; Second, extension mergers and acquisitions, through mergers and acquisitions, realize the integration of markets, resources and technologies, and achieve rapid development under the efficient internal control ability of enterprises.</p><p><b>In terms of the growth of endogenous power, the Group continued to accelerate the development and construction of independent projects.</b>According to the data of the interim report, as of the first half of 2021, the company independently developed 18 wind power and photovoltaic projects with construction indicators, with an installed capacity of 1.754 million kilowatts.</p><p>Among them, the \"Beijing-Zhangjiakou Olympic Wind Power Project\" undertaken by the company takes advantage of the abundant wind power resources in Zhangjiakou area and takes the opportunity of Beijing and Hebei Province's joint bid to host the Winter Olympic Committee to transmit the wind power in Zhangjiakou area to Beijing power grid for consumption by winter heating, and at the same time contributes to the pioneering initiative of 2022 Beijing Winter Olympic Committee to realize green power coverage in all venues for the first time in Olympic history.</p><p>Not only that, the construction of this project has enabled the development and utilization of abundant local wind energy resources, which has played a huge role in promoting the development of regional economy. At the same time, it has greatly optimized Beijing's energy structure, which is more conducive to the strategic deployment of the coordinated development of the central government's \"Beijing-Tianjin-Hebei integration\" and produces practical results.</p><p>It is understood that the total installed capacity of the project is 1.2 million kilowatts. Among them, Jingneng Clean Energy has a self-built capacity of 775,000 kilowatts. Up to now, the share transfer of Dongxu Shangyi 200,000 kilowatts wind power project and Guoxin Haojiaying 100,000 kilowatts wind power project has been completed. The installed capacity of Jingneng's clean energy management reaches 1.075 million kilowatts, and the total investment of the project is about 9 billion yuan.</p><p><b>In terms of extension expansion, we will vigorously expand our business through project mergers and acquisitions. As of the first half of 2021,</b>There are 13 wind power and photovoltaic projects under merger and acquisition, with an installed capacity of 1.486 million kilowatts. In July this year, the company entered into an equity transfer agreement between Kaiyang and Boyang with Ningxia Jiaze, and acquired 297.5MW wind power and photovoltaic project in Ningxia Hongsibao and 99MW wind power project in Ningxia Tongxin, which contributed to the installed capacity growth of Jingneng Clean Energy in the second half of the year.</p><p>It is worth mentioning that,<b>This acquisition is conducive to the intensive management of Jingneng Clean Energy Northwest Branch, and will form a good synergy effect with the company's existing assets. It can not only achieve the purpose of complementing each other's advantages, learning from each other's strengths, reducing costs and increasing efficiency, and coordinating businesses with each other, but also enable the company to form a nationwide and all-round strategic layout.</b></p><p><b>In fact, acquisitions and acquisitions are the only way to enhance the concentration of the new energy industry, and it is also a manifestation of the internal reshuffle of the industry.</b>With the increase of the cost of self-built projects in the overall industry, it has become one of the new business models of new energy enterprises to seek to acquire equity through mergers and acquisitions, and even acquire other industries to fill the shortcomings of business layout and expand the scale.</p><p>For new energy enterprises, changing from pure competition to cooperation can not only borrow from each other, but also avoid investment risks to a certain extent and maximize benefits. At the same time, we can also give full play to the strengths of each company and make the enterprise the best.</p><p>Therefore, in the long run, with the changes of the market environment, the future development model of new energy enterprises will not only practice hard and strengthen their own hard-core strength, but also obtain more resources in the form of mergers and acquisitions, reorganizations, etc., and try in many fields. \"Two-wheel drive\" and even \"four-wheel drive\" will be the future growth road of new energy enterprises. Jingneng Clean Energy has officially embarked on this high-speed road of \"becoming stronger and bigger\".</p><p></body></html></p>","source":"stock_gelonghui","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Business two-wheel drive improved strategic layout, Jingneng Clean Energy (0579.HK) interim results steadily improved</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBusiness two-wheel drive improved strategic layout, Jingneng Clean Energy (0579.HK) interim results steadily improved\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">格隆汇</strong><span class=\"h-time small\">2021-08-30 08:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><span>On August 26, Hong Kong stocks<a href=\"https://laohu8.com/S/00579\">Jingneng Clean Energy</a>(0579.HK) announced its 2021 interim results report: achieved operating income of RMB9.340 billion, representing a year-on-year increase of 12.81%; Profit before tax was RMB1,884 million, representing a year-on-year increase of 13.90%; Profit attributable to ordinary shareholders of the Company was RMB1,488 million, representing a year-on-year increase of 14.90%; Basic and diluted earnings per share were RMB18.05 cents.</span></p><p>This is an excellent report card. In the fiercely competitive market environment, in the first half of this year, the year-on-year growth rate of revenue and net profit of Jingneng Clean Energy both achieved double-digit growth. It can be said that there is progress in \"stability\" and full momentum for progress.</p><p><b><font color=\"#ff0000\">Steady business growth and further consolidation of industry position</font></b></p><p>Through the semi-annual performance report released by Jingneng Clean Energy, it can be found that while the operating performance has grown steadily, it has performed well in many business dimensions and has been continuously optimized.</p><p><b>The installed capacity has steadily increased,</b>As of June 30, 2021, the total installed capacity of the Company was 11.215 million kilowatts, representing a year-on-year increase of 14%, of which, the newly installed capacity of the wind power business segment was 349,000 kilowatts, all of which came from self-built projects.</p><p><b>The power generation showed a large increase.</b>As of June 30, 2021, the total power generation of the Company's holding was 16.179 billion kWh, representing a year-on-year increase of 17.73%.</p><p>Among which, the power generation of gas-fired power generation and heating business segment increased by 8.08% year-on-year;<b>The power generation of wind power business segment increased by 44.43% year-on-year; The power generation of photovoltaic power generation business segment increased by 37.87% year-on-year, significantly higher than the national industry level in the same period.</b></p><p><b>In summary,</b>Throughout the first half of 2021, Jingneng Clean Energy leveraged on its own soft and hard strengths and fully leveraged its diversified competitive advantages to achieve steady growth in various business segments.</p><p>In particular, the photovoltaic sector has exceeded the national level in the same period, fully catering to the development concepts of \"30,60\" and \"carbon peak and carbon neutrality\", further consolidating the company's industry leading position as a local new energy state-owned enterprise.</p><p><b><font color=\"#ff0000\">2. Independent development and project mergers and acquisitions are driven by two wheels, and the business synergy is highlighted</font></b></p><p>When judging the growth of an enterprise, there are often two points worth paying attention to. First, the growth of endogenous power depends on the accumulation of the enterprise itself; Second, extension mergers and acquisitions, through mergers and acquisitions, realize the integration of markets, resources and technologies, and achieve rapid development under the efficient internal control ability of enterprises.</p><p><b>In terms of the growth of endogenous power, the Group continued to accelerate the development and construction of independent projects.</b>According to the data of the interim report, as of the first half of 2021, the company independently developed 18 wind power and photovoltaic projects with construction indicators, with an installed capacity of 1.754 million kilowatts.</p><p>Among them, the \"Beijing-Zhangjiakou Olympic Wind Power Project\" undertaken by the company takes advantage of the abundant wind power resources in Zhangjiakou area and takes the opportunity of Beijing and Hebei Province's joint bid to host the Winter Olympic Committee to transmit the wind power in Zhangjiakou area to Beijing power grid for consumption by winter heating, and at the same time contributes to the pioneering initiative of 2022 Beijing Winter Olympic Committee to realize green power coverage in all venues for the first time in Olympic history.</p><p>Not only that, the construction of this project has enabled the development and utilization of abundant local wind energy resources, which has played a huge role in promoting the development of regional economy. At the same time, it has greatly optimized Beijing's energy structure, which is more conducive to the strategic deployment of the coordinated development of the central government's \"Beijing-Tianjin-Hebei integration\" and produces practical results.</p><p>It is understood that the total installed capacity of the project is 1.2 million kilowatts. Among them, Jingneng Clean Energy has a self-built capacity of 775,000 kilowatts. Up to now, the share transfer of Dongxu Shangyi 200,000 kilowatts wind power project and Guoxin Haojiaying 100,000 kilowatts wind power project has been completed. The installed capacity of Jingneng's clean energy management reaches 1.075 million kilowatts, and the total investment of the project is about 9 billion yuan.</p><p><b>In terms of extension expansion, we will vigorously expand our business through project mergers and acquisitions. As of the first half of 2021,</b>There are 13 wind power and photovoltaic projects under merger and acquisition, with an installed capacity of 1.486 million kilowatts. In July this year, the company entered into an equity transfer agreement between Kaiyang and Boyang with Ningxia Jiaze, and acquired 297.5MW wind power and photovoltaic project in Ningxia Hongsibao and 99MW wind power project in Ningxia Tongxin, which contributed to the installed capacity growth of Jingneng Clean Energy in the second half of the year.</p><p>It is worth mentioning that,<b>This acquisition is conducive to the intensive management of Jingneng Clean Energy Northwest Branch, and will form a good synergy effect with the company's existing assets. It can not only achieve the purpose of complementing each other's advantages, learning from each other's strengths, reducing costs and increasing efficiency, and coordinating businesses with each other, but also enable the company to form a nationwide and all-round strategic layout.</b></p><p><b>In fact, acquisitions and acquisitions are the only way to enhance the concentration of the new energy industry, and it is also a manifestation of the internal reshuffle of the industry.</b>With the increase of the cost of self-built projects in the overall industry, it has become one of the new business models of new energy enterprises to seek to acquire equity through mergers and acquisitions, and even acquire other industries to fill the shortcomings of business layout and expand the scale.</p><p>For new energy enterprises, changing from pure competition to cooperation can not only borrow from each other, but also avoid investment risks to a certain extent and maximize benefits. At the same time, we can also give full play to the strengths of each company and make the enterprise the best.</p><p>Therefore, in the long run, with the changes of the market environment, the future development model of new energy enterprises will not only practice hard and strengthen their own hard-core strength, but also obtain more resources in the form of mergers and acquisitions, reorganizations, etc., and try in many fields. \"Two-wheel drive\" and even \"four-wheel drive\" will be the future growth road of new energy enterprises. Jingneng Clean Energy has officially embarked on this high-speed road of \"becoming stronger and bigger\".</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://www.gelonghui.com/news/detail.html?id=608034\">格隆汇</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f01e4b782ba393cb7794f7764a5d7d90","relate_stocks":{"00579":"京能清洁能源"},"source_url":"https://www.gelonghui.com/news/detail.html?id=608034","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163702540","content_text":"8月26日，港股京能清洁能源(0579.HK)公布2021中期业绩报告：实现营业收入人民币93.40亿元，同比增长12.81%；除税前溢利为人民币18.84亿元，同比增长13.90%；公司普通股股东应占溢利为人民币14.88亿元，同比增长14.90%；每股基本及摊薄盈利人民币18.05分。这是一份优异的成绩单，在竞争激烈的市场环境下，今年上半年，京能清洁能源的营收、净利润同比增速双双取得两位数增长，可以说“稳”中有进，前进动力十足。1、业务稳健增长，行业地位进一步巩固通过京能清洁能源发布的半年度业绩报告，可以发现在经营业绩稳健增长的同时，在多个业务维度均有不俗表现，并且得到持续优化。装机容量稳步提高，截至2021年6月30日，公司控股总装机容量为1,121.5万千瓦，同比增长14%，其中，风力发电业务板块新增装机容量34.9万千瓦，全部来自于自建项目。发电量呈现较大幅度的增长。截至2021年6月30日，公司控股总发电量为161.79亿千瓦时，同比增长17.73%。其中燃气发电及供热业务板块发电量同比增长8.08%；风力发电业务板块发电量同比增长44.43%；光伏发电业务板块发电量同比增长37.87%，明显高于全国行业同期水平。总结来说，整个2021年上半年，京能清洁能源凭借其自身的软硬实力，充分发挥多元化的竞争优势，使得各个业务板块实现稳健增长。尤其是光伏板块更是超过全国同期的水平，充分迎合“30,60”、“碳达峰、碳中和”的发展理念，进一步巩固了公司作为地方新能源国企的行业领先地位。2、自主开发与项目并购双轮驱动，业务协同效应凸显评判一家企业的增长，往往有两个看点值得关注，其一，内生动力的增长，即依靠企业自身积累，厚积薄发；其二，外延式并购，通过收并购，实现市场、资源、技术的整合，在高效的企业内控能力之下，实现高速发展。 在内生动力增长方面，不断加快自主项目开发、建设的步伐。根据中报数据显示，截至2021年上半年，公司自主开发取得建设指标的风电、光伏项目18个，装机容量175.4万千瓦。 其中，公司承建的“京张奥运风电项目”，利用张家口地区丰富的风电资源，以北京市和河北省联合申办冬奥委会为契机，将张家口地区风电输送至北京电网以冬季供热方式进行消纳，同时为2022年北京冬奥委会在奥运史上首次实现全部场馆绿色电力覆盖的创举贡献首都国企的一份力量。不仅如此，该项目的建设让当地丰富的风能资源得到了开发与利用，对发展地区经济起到巨大的推动作用。同时极大地优化了北京能源结构，更有利于中央“京津冀一体化”协同发展的战略部署落地、产生实效。据了解，该项目总装机容量120万千瓦。其中京能清洁能源自建容量77.5万千瓦，截至目前，已经完成了东旭尚义20万千瓦风电项目、国新郝家营10万千瓦风电项目股转。京能清洁能源管理装机容量达107.5万千瓦，项目总投资约90亿元。在外延式扩张上，通过项目并购的方式大力拓展业务。截至2021年上半年，正在开展并购工作的风电、光伏项目共计13个，装机容量148.6万千瓦。今年7月份，公司与宁夏嘉泽订立了恺阳及博阳股权转让协议，收购了宁夏红寺堡297.5MW风电、光伏项目及宁夏同心99MW风电项目，为京能清洁能源下半年的装机容量增长贡献了一份力量。值得一提的是，此次收购有利于京能清洁能源西北分公司的集约化管理，将与公司既有资产形成较好的协同效应。不仅可以达到优势互补，取长补短，降本增效，业务相互协同的目的，还可以让公司形成全国化、全方位的战略布局。事实上，收购并购是新能源行业集中度增强的必经之路，也是行业内部洗牌的一种表现。随着整体行业自建项目成本的增加，寻求通过并购形式收购股权获得项目，甚至收购其他行业填补业态布局短板、扩大规模已成为新能源企业新的经营模式之一。对新能源企业而言，由之前的纯竞争转为合作，不仅可以相互借力，一定程度上规避投资风险，实现利益最大化。同时，还可以发挥各家所长，把企业做到最好。因此，长期来看，随着市场环境的变化，新能源企业未来的发展模式，除了苦练内功，增强自身的硬核实力之外，以并购、重组等形式来获取更多资源，多领域的尝试，“双轮驱动”以至“四轮驱动”将是新能源的企业未来成长之路，京能清洁能源已正式踏上了这条“做强、做大”的高速之路。","news_type":1,"symbols_score_info":{"00579":1}},"isVote":1,"tweetType":1,"viewCount":3567,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811109949,"gmtCreate":1630293486281,"gmtModify":1676530259693,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811109949","repostId":"1167910924","repostType":2,"isVote":1,"tweetType":1,"viewCount":3007,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810814571,"gmtCreate":1629962150993,"gmtModify":1676530185284,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810814571","repostId":"2162106440","repostType":2,"repost":{"id":"2162106440","kind":"news","pubTimestamp":1629959831,"share":"https://ttm.financial/m/news/2162106440?lang=en_US&edition=fundamental","pubTime":"2021-08-26 14:37","market":"sh","language":"zh","title":"Morgan Stanley: Give WuXi Biologics an \"overweight\" rating, the target price rose 3.6% to HK$170","url":"https://stock-news.laohu8.com/highlight/detail?id=2162106440","media":"智通财经","summary":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。 ...","content":"<p><html><body><div>Morgan Stanley released a research report saying that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Overweight\" rating, the target price was raised from HK$164 to HK$170, and the earnings forecast for 2021-24 was raised by 1% to 9% to reflect the strong first half performance, and the revenue and gross profit forecast were also raised simultaneously.</p><p><strong>follow<a href=\"https://laohu8.com/S/300033\">Flush</a>Finance (ths518), Get More Opportunities</strong></p><p><span></span><div><span>Editor in Charge: cjh</span></div></div></body></html></p>","source":"tonghuashun","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley: Give WuXi Biologics an \"overweight\" rating, the target price rose 3.6% to HK$170</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley: Give WuXi Biologics an \"overweight\" rating, the target price rose 3.6% to HK$170\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-26 14:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div>Morgan Stanley released a research report saying that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Overweight\" rating, the target price was raised from HK$164 to HK$170, and the earnings forecast for 2021-24 was raised by 1% to 9% to reflect the strong first half performance, and the revenue and gross profit forecast were also raised simultaneously.</p><p><strong>follow<a href=\"https://laohu8.com/S/300033\">Flush</a>Finance (ths518), Get More Opportunities</strong></p><p><span></span><div><span>Editor in Charge: cjh</span></div></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16","relate_stocks":{"02269":"药明生物"},"source_url":"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","article_id":"2162106440","content_text":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。\n关注同花顺财经（ths518），获取更多机会\n\n责任编辑：cjh","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":2811,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837654134,"gmtCreate":1629886521628,"gmtModify":1676530162487,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837654134","repostId":"2162031026","repostType":2,"repost":{"id":"2162031026","kind":"news","pubTimestamp":1629875170,"share":"https://ttm.financial/m/news/2162031026?lang=en_US&edition=fundamental","pubTime":"2021-08-25 15:06","market":"hk","language":"zh","title":"Zhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments","url":"https://stock-news.laohu8.com/highlight/detail?id=2162031026","media":"智通财经","summary":"智通财经APP获悉，中泰证券发布研究报告称，维持药明生物“买入”评级，认为公司是全球生物药外包服务行业稀缺标的，所处行业高景气、公司优势凸显，后续随着现有项目进入商业化，以及XDC、疫苗、双抗等平台加速兑现，长期空间广阔，未来可期。中泰证券主要观点如下：业绩超预期，归母净利润高于业绩预告。前次业绩预告2021H1归母净利润同比增长135%，实际增长150.3%，高于预期。","content":"<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/600918\">Zhongtai Securities</a>Released a research report saying that maintaining<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Buy\" rating, believing that the company is a scarce target in the global biopharmaceutical outsourcing service industry, with high prosperity in the industry and prominent advantages of the company. Subsequently, with the commercialization of existing projects, XDC, vaccines, double antibodies and other platforms to accelerate the realization, the long-term space is broad, and the future is promising.</p><p><strong>Event:</strong>The company released its results for the first half of 2021, and achieved operating income of 4.41 billion yuan during the period, representing a year-on-year increase of 126.7%; Net profit attributable to the parent was 1.84 billion yuan, a year-on-year increase of 150.3%; The adjusted net profit attributable to the parent was 1.77 billion yuan, a year-on-year increase of 163%.</p><p><strong>The main views of Zhongtai Securities are as follows:</strong></p><p><strong>The performance exceeded expectations, and the net profit attributable to the parent was higher than the performance forecast.</strong></p><p>The previous performance forecast 2021H1 net profit attributable to the parent increased by 135% year-on-year, and the actual growth was 150.3%, which was higher than expected. The Bank believes that it is mainly due to:</p><p>1) The volume of late clinical and commercialization projects increased rapidly, including the clinical stage revenue of 1.94 billion yuan (+109.2% year-on-year) and the commercialization stage revenue of 889 million yuan (+2923.5%);</p><p>2) the rapid recovery of demand after the normalization of overseas epidemic, with revenue from North America of RMB2.19 billion (+149.3% year-on-year) and revenue from Europe of RMB990 million (+706.8% year-on-year) in 2021H1;</p><p>3) continuous optimization of management capabilities and continuous improvement of operational efficiency, with gross profit margin of approximately 52.1% (+11.6pp), net profit margin of approximately 41.8% (+3.9pp) and period expense ratio of approximately 12.4% (-8.2pp) in 2021H1;</p><p>4) Low base last year: In the first half of last year, the overall base was low due to the epidemic disturbance, with 740 million (+63.6%) attributable to the parent in 2020H1. However, compared with the net profit attributable to the parent in 2019H1, the company's CAGR from 2019H1 to 2021H1 was about 102.3%, with a rapid growth.</p><p><strong>CMO's logic of heavy volume continues to be realized, and the strategy of following and winning molecules is progressing smoothly, which is expected to accelerate the growth of overall performance.</strong></p><p>Adhering to the strategy of following and winning molecules, as of June 30, the company extended 27 projects (14 pre-clinical to clinical, 2 phase III to commercial) in the first half of the year, introduced 20 clinical projects externally (+400%, including 9 clinical phase II and 4 clinical phase III), added 79 projects, and the overall number of projects reached 408 (+42.7% year-on-year compared with 2020H1), including 212 pre-clinical (+50.4%), 160 early (phase I and phase II) projects (+28%), 32 phase III projects (+68.4%), and 4 commercial projects (three new).</p><p>In addition, due to the rapid growth of the number of projects, the company's orders in hand continue to increase rapidly. It is expected that in the next three years, the total amount of orders completed will reach 2.25 billion USD (+143.1%), and the total amount of uncompleted orders will be about 12.46 billion USD (+31.7%), of which the outstanding service orders will be 7.23 billion USD (+25.2%). It is expected that the bank will have seven commercialization projects in 2021, which is expected to promote a new round of heavy volume in the CDMO sector and accelerate the overall performance growth.</p><p><strong>Advanced XDC, vaccine and dual antibody platforms bring new growth momentum.</strong></p><p><strong>XDC:</strong>The company's XDC drug R&D platform has undertaken 48 ADC projects (+60%) with the advantages of WuXiDAR4 technology, and 15 CDMO projects are already underway, and the commercialization volume can be expected;</p><p><strong>WuxiVaccine:</strong>Nine vaccine orders are being executed (up 8 year-on-year), and the orders in hand have increased to US$3.3 billion. WuXi Haide is expected to be put into operation in 2022, which is expected to continue to bring incremental performance.</p><p><strong>Double antibody:</strong>WuxiBody ™ Undertake 31 projects (+19.2%), and expect to add 1~2 IND applications in 2021, which is expected to extend CDMO to gradually contribute new increments.</p><p><strong>Earnings Forecast and Investment Advice:</strong>The bank estimates that the company's revenue from 2021 to 2023 will be 9.36, 13.84 and 19.4 billion yuan, representing a year-on-year increase of 66.7%, 47.9% and 40.2%, and the net profit attributable to the parent will be 2.82, 4.17 and 5.88 billion yuan, representing a year-on-year increase of 67.1%, 47.6% and 41.2%, corresponding to EPS of 0.67, 0.98 and 1.39 yuan.</p><p><strong>Risk warning events:</strong>The public information used in the research report may be subject to the risk of information lag or updating in a timely manner, proposed acquisition<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>The risks of the progress of China's biologics production base project being less than expected, the investment in biologics research and development being less than expected, and the risk of loss of core technical personnel.</p><p></body></html></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-25 15:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/600918\">Zhongtai Securities</a>Released a research report saying that maintaining<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Buy\" rating, believing that the company is a scarce target in the global biopharmaceutical outsourcing service industry, with high prosperity in the industry and prominent advantages of the company. Subsequently, with the commercialization of existing projects, XDC, vaccines, double antibodies and other platforms to accelerate the realization, the long-term space is broad, and the future is promising.</p><p><strong>Event:</strong>The company released its results for the first half of 2021, and achieved operating income of 4.41 billion yuan during the period, representing a year-on-year increase of 126.7%; Net profit attributable to the parent was 1.84 billion yuan, a year-on-year increase of 150.3%; The adjusted net profit attributable to the parent was 1.77 billion yuan, a year-on-year increase of 163%.</p><p><strong>The main views of Zhongtai Securities are as follows:</strong></p><p><strong>The performance exceeded expectations, and the net profit attributable to the parent was higher than the performance forecast.</strong></p><p>The previous performance forecast 2021H1 net profit attributable to the parent increased by 135% year-on-year, and the actual growth was 150.3%, which was higher than expected. The Bank believes that it is mainly due to:</p><p>1) The volume of late clinical and commercialization projects increased rapidly, including the clinical stage revenue of 1.94 billion yuan (+109.2% year-on-year) and the commercialization stage revenue of 889 million yuan (+2923.5%);</p><p>2) the rapid recovery of demand after the normalization of overseas epidemic, with revenue from North America of RMB2.19 billion (+149.3% year-on-year) and revenue from Europe of RMB990 million (+706.8% year-on-year) in 2021H1;</p><p>3) continuous optimization of management capabilities and continuous improvement of operational efficiency, with gross profit margin of approximately 52.1% (+11.6pp), net profit margin of approximately 41.8% (+3.9pp) and period expense ratio of approximately 12.4% (-8.2pp) in 2021H1;</p><p>4) Low base last year: In the first half of last year, the overall base was low due to the epidemic disturbance, with 740 million (+63.6%) attributable to the parent in 2020H1. However, compared with the net profit attributable to the parent in 2019H1, the company's CAGR from 2019H1 to 2021H1 was about 102.3%, with a rapid growth.</p><p><strong>CMO's logic of heavy volume continues to be realized, and the strategy of following and winning molecules is progressing smoothly, which is expected to accelerate the growth of overall performance.</strong></p><p>Adhering to the strategy of following and winning molecules, as of June 30, the company extended 27 projects (14 pre-clinical to clinical, 2 phase III to commercial) in the first half of the year, introduced 20 clinical projects externally (+400%, including 9 clinical phase II and 4 clinical phase III), added 79 projects, and the overall number of projects reached 408 (+42.7% year-on-year compared with 2020H1), including 212 pre-clinical (+50.4%), 160 early (phase I and phase II) projects (+28%), 32 phase III projects (+68.4%), and 4 commercial projects (three new).</p><p>In addition, due to the rapid growth of the number of projects, the company's orders in hand continue to increase rapidly. It is expected that in the next three years, the total amount of orders completed will reach 2.25 billion USD (+143.1%), and the total amount of uncompleted orders will be about 12.46 billion USD (+31.7%), of which the outstanding service orders will be 7.23 billion USD (+25.2%). It is expected that the bank will have seven commercialization projects in 2021, which is expected to promote a new round of heavy volume in the CDMO sector and accelerate the overall performance growth.</p><p><strong>Advanced XDC, vaccine and dual antibody platforms bring new growth momentum.</strong></p><p><strong>XDC:</strong>The company's XDC drug R&D platform has undertaken 48 ADC projects (+60%) with the advantages of WuXiDAR4 technology, and 15 CDMO projects are already underway, and the commercialization volume can be expected;</p><p><strong>WuxiVaccine:</strong>Nine vaccine orders are being executed (up 8 year-on-year), and the orders in hand have increased to US$3.3 billion. WuXi Haide is expected to be put into operation in 2022, which is expected to continue to bring incremental performance.</p><p><strong>Double antibody:</strong>WuxiBody ™ Undertake 31 projects (+19.2%), and expect to add 1~2 IND applications in 2021, which is expected to extend CDMO to gradually contribute new increments.</p><p><strong>Earnings Forecast and Investment Advice:</strong>The bank estimates that the company's revenue from 2021 to 2023 will be 9.36, 13.84 and 19.4 billion yuan, representing a year-on-year increase of 66.7%, 47.9% and 40.2%, and the net profit attributable to the parent will be 2.82, 4.17 and 5.88 billion yuan, representing a year-on-year increase of 67.1%, 47.6% and 41.2%, corresponding to EPS of 0.67, 0.98 and 1.39 yuan.</p><p><strong>Risk warning events:</strong>The public information used in the research report may be subject to the risk of information lag or updating in a timely manner, proposed acquisition<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>The risks of the progress of China's biologics production base project being less than expected, the investment in biologics research and development being less than expected, and the risk of loss of core technical personnel.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/543594.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{"600918":"中泰证券","02269":"药明生物"},"source_url":"http://www.zhitongcaijing.com/content/detail/543594.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162031026","content_text":"智通财经APP获悉，中泰证券发布研究报告称，维持药明生物(02269)“买入”评级，认为公司是全球生物药外包服务行业稀缺标的，所处行业高景气、公司优势凸显，后续随着现有项目进入商业化，以及XDC、疫苗、双抗等平台加速兑现，长期空间广阔，未来可期。事件：公司发布2021年上半年业绩，期内实现营业收入44.1亿元，同比增长126.7%;归母净利润18.4亿元，同比增长150.3%;经调整归母净利润17.7亿元，同比增长163%。中泰证券主要观点如下：业绩超预期，归母净利润高于业绩预告。前次业绩预告2021H1归母净利润同比增长135%，实际增长150.3%，高于预期。该行认为主要源于：1)临床后期及商业化项目快速放量，其中临床阶段收入19.4亿元(同比+109.2%)，商业化阶段收入8.89亿(+2923.5%);2)海外疫情常态化后需求的快速恢复，2021H1北美收入21.9亿元(同比+149.3%)，欧洲收入9.9亿元(同比+706.8%);3)管理能力持续优化，运营效率持续提升，2021H1毛利率约为52.1%(+11.6pp)，净利率约为41.8%(+3.9pp)，期间费用率约12.4%(-8.2pp);4)去年基数低：去年上半年因疫情扰动导致整体基数较低，2020H1归母7.4亿(+63.6%)，但对比2019H1归母净利润，公司2019H1-2021H1CAGR约102.3%，增长迅猛。CMO放量逻辑持续兑现，跟随并赢得分子策略进展顺利，有望带动整体业绩加速增长。公司秉承跟随及赢得分子策略，截止6月30日，上半年延伸27个项目(14个临床前至临床、2个III期至商业化)，外部引进20个临床项目(+400%，其中临床II期9个、临床III期4个)，新增79个项目，整体项目数达408个(较2020H1同比+42.7%)，其中临床前212个(+50.4%)、早期(I期、II期)项目数达160个(+28%)，III期项目达32个(+68.4%)，商业化项目4个(新增三个)。此外，源于项目数不断快速增长，公司在手订单持续高增，预计未来三年能够完成订单总额达22.5亿美元(+143.1%)，未完成订单总额约124.6亿美元(+31.7%)，其中未完成服务订单72.3亿美元(+25.2%)。该行预计2021年将有7个商业化项目落地，有望推动CDMO板块新一轮放量，带动整体业绩提速增长。先进的XDC、疫苗、双抗平台带来增长新动能。XDC：公司XDC药物研发平台凭借WuXiDAR4技术优势承接48个ADC项目(+60%)，已有15个CDMO项目正在进行，商业化放量可期;WuxiVaccine：9个疫苗订单正在执行(同比增长8个)，在手订单提升至33亿美元，药明海德预计2022年投入运营，有望持续带来业绩增量。双抗：WuxiBody™承接31个项目(+19.2%)，预计2021年新增1~2个IND申请，有望延伸CDMO逐步贡献新增量。盈利预测与投资建议：该行预计2021-2023年公司收入93.6、138.4和194亿元，同比增长66.7%、47.9%、40.2%，归母净利润28.2、41.7和58.8亿元，同比增长67.1%、47.6%、41.2%，对应EPS为0.67、0.98、1.39元。风险提示事件：研究报告使用的公开资料可能存在信息滞后或更新不及时的风险、拟收购辉瑞中国生物药生产基地项目进展不及预期风险、生物药研发投入不及预期、核心技术人员流失的风险。","news_type":1,"symbols_score_info":{"600918":1,"02269":1}},"isVote":1,"tweetType":1,"viewCount":3400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835151166,"gmtCreate":1629696705355,"gmtModify":1676530102959,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835151166","repostId":"2161725272","repostType":2,"repost":{"id":"2161725272","kind":"news","pubTimestamp":1629684392,"share":"https://ttm.financial/m/news/2161725272?lang=en_US&edition=fundamental","pubTime":"2021-08-23 10:06","market":"us","language":"zh","title":"[Moving stocks] WuXi Biologics (02269.HK) rose 3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2161725272","media":"金融界网站","summary":"【财华社讯】药明生物(02269.HK)截至10:06上涨3.13%，现报108.6港元，涨3.3港元。成交375万股，涉资3.967亿元。（出处：FinetAI）","content":"<p><html><body><div>[Caihua News]<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269.HK) rose 3.13% as of 10:06 and is now traded at HK$108.6, up HK$3.3. 3.75 million shares were traded, involving 396.7 million yuan. (Source: FinetAI)</p><p><div></div></div></body></html></p>","source":"jinrongjie_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[Moving stocks] WuXi Biologics (02269.HK) rose 3.13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[Moving stocks] WuXi Biologics (02269.HK) rose 3.13%\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">金融界网站</strong><span class=\"h-time small\">2021-08-23 10:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div>[Caihua News]<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269.HK) rose 3.13% as of 10:06 and is now traded at HK$108.6, up HK$3.3. 3.75 million shares were traded, involving 396.7 million yuan. (Source: FinetAI)</p><p><div></div></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://hk.jrj.com.cn/2021/08/23100633301119.shtml\">金融界网站</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","relate_stocks":{"02269":"药明生物"},"source_url":"http://hk.jrj.com.cn/2021/08/23100633301119.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161725272","content_text":"【财华社讯】药明生物(02269.HK)截至10:06上涨3.13%，现报108.6港元，涨3.3港元。成交375万股，涉资3.967亿元。（出处：FinetAI）","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":3315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320086108,"gmtCreate":1614990798804,"gmtModify":1704777945890,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320086108","repostId":"1183532320","repostType":2,"repost":{"id":"1183532320","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614957526,"share":"https://ttm.financial/m/news/1183532320?lang=en_US&edition=fundamental","pubTime":"2021-03-05 23:18","market":"us","language":"zh","title":"Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183532320","media":"老虎资讯综合","summary":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.","content":"<p>On Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>It turned up in the intraday session, once rising by more than 10%, and as of press time, it rose by 5.09%. It fell more than 16% at the beginning of the session.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, GSX announced its unaudited financial reports for the fourth quarter of fiscal 2020 and the full year of fiscal 2020. According to the report, GSX's revenue in Q4 2020 reached 2.211 billion yuan, a year-on-year increase of 136.5%, and the number of regular-price courses paid increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report of fiscal year 2020 is the first quarter report card after GSX merged all K12 businesses into \"Gaotu Classroom\". The revenue of K12 online courses was 1.975 billion yuan, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. The cash income of K12 online courses was 2.923 billion yuan, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash income; The number of regular-priced K12 online courses paid reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of all regular-priced courses paid by the company.</p><p>At the same time, as of December 31, 2020, GSX achieved revenue of 7.125 billion yuan in fiscal year 2020, a year-on-year increase of 236.9%, and the number of regular-price courses paid reached 5.871 million, a year-on-year increase of 168.4%. Among them, the revenue of K12 online courses was 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people who paid for regular price courses of K12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of GSX, said: \"In the fourth quarter of 2020, revenue reached a new high, reaching 2.21 billion yuan. In 2020, operating income increased by 236.9% year-on-year to 7.12 billion yuan. GSX achieved such growth rate and scale through efficient operation. In the fourth quarter alone, the operating net cash flow in a single quarter was as high as 636 million yuan, and the annual operating net cash flow continued to be positive.\"</p><p>It is worth noting that on March 2nd this year, GSX announced that the independent investigation on a number of short-selling reports in 2020 had basically ended. According to the investigation results feedback from third-party professional consultants hired by the company's independent audit committee, no evidence of material adverse impact on the company's historical financial statements was found.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWho Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-05 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>It turned up in the intraday session, once rising by more than 10%, and as of press time, it rose by 5.09%. It fell more than 16% at the beginning of the session.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, GSX announced its unaudited financial reports for the fourth quarter of fiscal 2020 and the full year of fiscal 2020. According to the report, GSX's revenue in Q4 2020 reached 2.211 billion yuan, a year-on-year increase of 136.5%, and the number of regular-price courses paid increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report of fiscal year 2020 is the first quarter report card after GSX merged all K12 businesses into \"Gaotu Classroom\". The revenue of K12 online courses was 1.975 billion yuan, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. The cash income of K12 online courses was 2.923 billion yuan, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash income; The number of regular-priced K12 online courses paid reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of all regular-priced courses paid by the company.</p><p>At the same time, as of December 31, 2020, GSX achieved revenue of 7.125 billion yuan in fiscal year 2020, a year-on-year increase of 236.9%, and the number of regular-price courses paid reached 5.871 million, a year-on-year increase of 168.4%. Among them, the revenue of K12 online courses was 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people who paid for regular price courses of K12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of GSX, said: \"In the fourth quarter of 2020, revenue reached a new high, reaching 2.21 billion yuan. In 2020, operating income increased by 236.9% year-on-year to 7.12 billion yuan. GSX achieved such growth rate and scale through efficient operation. In the fourth quarter alone, the operating net cash flow in a single quarter was as high as 636 million yuan, and the annual operating net cash flow continued to be positive.\"</p><p>It is worth noting that on March 2nd this year, GSX announced that the independent investigation on a number of short-selling reports in 2020 had basically ended. According to the investigation results feedback from third-party professional consultants hired by the company's independent audit committee, no evidence of material adverse impact on the company's historical financial statements was found.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f49cfbbad938b58f9d764c4f5e672e9","relate_stocks":{"GSX":"Tradr 2X Long GS Daily ETF"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183532320","content_text":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.11亿元，同比增长136.5%，正价课付费人次同比增长107.6%达227.5万。2020财年Q4财报是跟谁学将K12业务全部合并至“高途课堂”后的首季成绩单，K12在线课程收入为19.75亿元，同比增长155.6%，占公司全部收入的89.33%，K12在线课程的现金收入为29.23亿元人民币，同比增长109.8%,，占公司全部现金收入的92.90%；K12在线课程正价课付费人次达到213.9万，同比增长112.8%，占公司全部正价课付费人次的94%。同时，截止到2020年12月31日，跟谁学2020财年全年实现收入71.25亿元，同比增长236.9%，正价课付费人次达587.1万，同比增长168.4%。其中，K12 在线课程收入为62.37亿元，同比增长265.5%，K12在线课程正价课付费人次达542.9万，同比增长177.3%。跟谁学创始人、董事长兼CEO陈向东表示：“2020年第四季度收入创造新高，达到22.1亿元。2020年营业收入同比增长了236.9%，为71.2亿元。跟谁学取得这样的增速和规模是通过高效率的运营达成的，仅第四季度单季经营净现金流就高达6.36亿元，全年经营净现金流也持续为正”。值得关注的是，今年3月2日，跟谁学发布公告称，针对2020年多份做空报告开展的独立调查已基本结束，根据公司独立审计委员会聘请的第三方专业顾问反馈的调查结果，没有发现对公司历史财务报表有重大不利影响的证据。","news_type":1,"symbols_score_info":{"GSX":0.9}},"isVote":1,"tweetType":1,"viewCount":3520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320086094,"gmtCreate":1614990789718,"gmtModify":1704777945082,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320086094","repostId":"1183532320","repostType":2,"repost":{"id":"1183532320","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614957526,"share":"https://ttm.financial/m/news/1183532320?lang=en_US&edition=fundamental","pubTime":"2021-03-05 23:18","market":"us","language":"zh","title":"Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183532320","media":"老虎资讯综合","summary":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.","content":"<p>On Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>It turned up in the intraday session, once rising by more than 10%, and as of press time, it rose by 5.09%. It fell more than 16% at the beginning of the session.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, GSX announced its unaudited financial reports for the fourth quarter of fiscal 2020 and the full year of fiscal 2020. According to the report, GSX's revenue in Q4 2020 reached 2.211 billion yuan, a year-on-year increase of 136.5%, and the number of regular-price courses paid increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report of fiscal year 2020 is the first quarter report card after GSX merged all K12 businesses into \"Gaotu Classroom\". The revenue of K12 online courses was 1.975 billion yuan, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. The cash income of K12 online courses was 2.923 billion yuan, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash income; The number of regular-priced K12 online courses paid reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of all regular-priced courses paid by the company.</p><p>At the same time, as of December 31, 2020, GSX achieved revenue of 7.125 billion yuan in fiscal year 2020, a year-on-year increase of 236.9%, and the number of regular-price courses paid reached 5.871 million, a year-on-year increase of 168.4%. Among them, the revenue of K12 online courses was 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people who paid for regular price courses of K12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of GSX, said: \"In the fourth quarter of 2020, revenue reached a new high, reaching 2.21 billion yuan. In 2020, operating income increased by 236.9% year-on-year to 7.12 billion yuan. GSX achieved such growth rate and scale through efficient operation. In the fourth quarter alone, the operating net cash flow in a single quarter was as high as 636 million yuan, and the annual operating net cash flow continued to be positive.\"</p><p>It is worth noting that on March 2nd this year, GSX announced that the independent investigation on a number of short-selling reports in 2020 had basically ended. According to the investigation results feedback from third-party professional consultants hired by the company's independent audit committee, no evidence of material adverse impact on the company's historical financial statements was found.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWho Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-05 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>It turned up in the intraday session, once rising by more than 10%, and as of press time, it rose by 5.09%. It fell more than 16% at the beginning of the session.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, GSX announced its unaudited financial reports for the fourth quarter of fiscal 2020 and the full year of fiscal 2020. According to the report, GSX's revenue in Q4 2020 reached 2.211 billion yuan, a year-on-year increase of 136.5%, and the number of regular-price courses paid increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report of fiscal year 2020 is the first quarter report card after GSX merged all K12 businesses into \"Gaotu Classroom\". The revenue of K12 online courses was 1.975 billion yuan, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. The cash income of K12 online courses was 2.923 billion yuan, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash income; The number of regular-priced K12 online courses paid reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of all regular-priced courses paid by the company.</p><p>At the same time, as of December 31, 2020, GSX achieved revenue of 7.125 billion yuan in fiscal year 2020, a year-on-year increase of 236.9%, and the number of regular-price courses paid reached 5.871 million, a year-on-year increase of 168.4%. Among them, the revenue of K12 online courses was 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people who paid for regular price courses of K12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of GSX, said: \"In the fourth quarter of 2020, revenue reached a new high, reaching 2.21 billion yuan. In 2020, operating income increased by 236.9% year-on-year to 7.12 billion yuan. GSX achieved such growth rate and scale through efficient operation. In the fourth quarter alone, the operating net cash flow in a single quarter was as high as 636 million yuan, and the annual operating net cash flow continued to be positive.\"</p><p>It is worth noting that on March 2nd this year, GSX announced that the independent investigation on a number of short-selling reports in 2020 had basically ended. According to the investigation results feedback from third-party professional consultants hired by the company's independent audit committee, no evidence of material adverse impact on the company's historical financial statements was found.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f49cfbbad938b58f9d764c4f5e672e9","relate_stocks":{"GSX":"Tradr 2X Long GS Daily ETF"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183532320","content_text":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.11亿元，同比增长136.5%，正价课付费人次同比增长107.6%达227.5万。2020财年Q4财报是跟谁学将K12业务全部合并至“高途课堂”后的首季成绩单，K12在线课程收入为19.75亿元，同比增长155.6%，占公司全部收入的89.33%，K12在线课程的现金收入为29.23亿元人民币，同比增长109.8%,，占公司全部现金收入的92.90%；K12在线课程正价课付费人次达到213.9万，同比增长112.8%，占公司全部正价课付费人次的94%。同时，截止到2020年12月31日，跟谁学2020财年全年实现收入71.25亿元，同比增长236.9%，正价课付费人次达587.1万，同比增长168.4%。其中，K12 在线课程收入为62.37亿元，同比增长265.5%，K12在线课程正价课付费人次达542.9万，同比增长177.3%。跟谁学创始人、董事长兼CEO陈向东表示：“2020年第四季度收入创造新高，达到22.1亿元。2020年营业收入同比增长了236.9%，为71.2亿元。跟谁学取得这样的增速和规模是通过高效率的运营达成的，仅第四季度单季经营净现金流就高达6.36亿元，全年经营净现金流也持续为正”。值得关注的是，今年3月2日，跟谁学发布公告称，针对2020年多份做空报告开展的独立调查已基本结束，根据公司独立审计委员会聘请的第三方专业顾问反馈的调查结果，没有发现对公司历史财务报表有重大不利影响的证据。","news_type":1,"symbols_score_info":{"GSX":0.9}},"isVote":1,"tweetType":1,"viewCount":2402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":320086108,"gmtCreate":1614990798804,"gmtModify":1704777945890,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320086108","repostId":"1183532320","repostType":2,"repost":{"id":"1183532320","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614957526,"share":"https://ttm.financial/m/news/1183532320?lang=en_US&edition=fundamental","pubTime":"2021-03-05 23:18","market":"us","language":"zh","title":"Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183532320","media":"老虎资讯综合","summary":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.","content":"<p>On Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>It turned up in the intraday session, once rising by more than 10%, and as of press time, it rose by 5.09%. It fell more than 16% at the beginning of the session.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, GSX announced its unaudited financial reports for the fourth quarter of fiscal 2020 and the full year of fiscal 2020. According to the report, GSX's revenue in Q4 2020 reached 2.211 billion yuan, a year-on-year increase of 136.5%, and the number of regular-price courses paid increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report of fiscal year 2020 is the first quarter report card after GSX merged all K12 businesses into \"Gaotu Classroom\". The revenue of K12 online courses was 1.975 billion yuan, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. The cash income of K12 online courses was 2.923 billion yuan, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash income; The number of regular-priced K12 online courses paid reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of all regular-priced courses paid by the company.</p><p>At the same time, as of December 31, 2020, GSX achieved revenue of 7.125 billion yuan in fiscal year 2020, a year-on-year increase of 236.9%, and the number of regular-price courses paid reached 5.871 million, a year-on-year increase of 168.4%. Among them, the revenue of K12 online courses was 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people who paid for regular price courses of K12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of GSX, said: \"In the fourth quarter of 2020, revenue reached a new high, reaching 2.21 billion yuan. In 2020, operating income increased by 236.9% year-on-year to 7.12 billion yuan. GSX achieved such growth rate and scale through efficient operation. In the fourth quarter alone, the operating net cash flow in a single quarter was as high as 636 million yuan, and the annual operating net cash flow continued to be positive.\"</p><p>It is worth noting that on March 2nd this year, GSX announced that the independent investigation on a number of short-selling reports in 2020 had basically ended. According to the investigation results feedback from third-party professional consultants hired by the company's independent audit committee, no evidence of material adverse impact on the company's historical financial statements was found.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWho Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-05 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>It turned up in the intraday session, once rising by more than 10%, and as of press time, it rose by 5.09%. It fell more than 16% at the beginning of the session.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, GSX announced its unaudited financial reports for the fourth quarter of fiscal 2020 and the full year of fiscal 2020. According to the report, GSX's revenue in Q4 2020 reached 2.211 billion yuan, a year-on-year increase of 136.5%, and the number of regular-price courses paid increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report of fiscal year 2020 is the first quarter report card after GSX merged all K12 businesses into \"Gaotu Classroom\". The revenue of K12 online courses was 1.975 billion yuan, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. The cash income of K12 online courses was 2.923 billion yuan, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash income; The number of regular-priced K12 online courses paid reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of all regular-priced courses paid by the company.</p><p>At the same time, as of December 31, 2020, GSX achieved revenue of 7.125 billion yuan in fiscal year 2020, a year-on-year increase of 236.9%, and the number of regular-price courses paid reached 5.871 million, a year-on-year increase of 168.4%. Among them, the revenue of K12 online courses was 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people who paid for regular price courses of K12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of GSX, said: \"In the fourth quarter of 2020, revenue reached a new high, reaching 2.21 billion yuan. In 2020, operating income increased by 236.9% year-on-year to 7.12 billion yuan. GSX achieved such growth rate and scale through efficient operation. In the fourth quarter alone, the operating net cash flow in a single quarter was as high as 636 million yuan, and the annual operating net cash flow continued to be positive.\"</p><p>It is worth noting that on March 2nd this year, GSX announced that the independent investigation on a number of short-selling reports in 2020 had basically ended. According to the investigation results feedback from third-party professional consultants hired by the company's independent audit committee, no evidence of material adverse impact on the company's historical financial statements was found.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f49cfbbad938b58f9d764c4f5e672e9","relate_stocks":{"GSX":"Tradr 2X Long GS Daily ETF"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183532320","content_text":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.11亿元，同比增长136.5%，正价课付费人次同比增长107.6%达227.5万。2020财年Q4财报是跟谁学将K12业务全部合并至“高途课堂”后的首季成绩单，K12在线课程收入为19.75亿元，同比增长155.6%，占公司全部收入的89.33%，K12在线课程的现金收入为29.23亿元人民币，同比增长109.8%,，占公司全部现金收入的92.90%；K12在线课程正价课付费人次达到213.9万，同比增长112.8%，占公司全部正价课付费人次的94%。同时，截止到2020年12月31日，跟谁学2020财年全年实现收入71.25亿元，同比增长236.9%，正价课付费人次达587.1万，同比增长168.4%。其中，K12 在线课程收入为62.37亿元，同比增长265.5%，K12在线课程正价课付费人次达542.9万，同比增长177.3%。跟谁学创始人、董事长兼CEO陈向东表示：“2020年第四季度收入创造新高，达到22.1亿元。2020年营业收入同比增长了236.9%，为71.2亿元。跟谁学取得这样的增速和规模是通过高效率的运营达成的，仅第四季度单季经营净现金流就高达6.36亿元，全年经营净现金流也持续为正”。值得关注的是，今年3月2日，跟谁学发布公告称，针对2020年多份做空报告开展的独立调查已基本结束，根据公司独立审计委员会聘请的第三方专业顾问反馈的调查结果，没有发现对公司历史财务报表有重大不利影响的证据。","news_type":1,"symbols_score_info":{"GSX":0.9}},"isVote":1,"tweetType":1,"viewCount":3520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320086094,"gmtCreate":1614990789718,"gmtModify":1704777945082,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/320086094","repostId":"1183532320","repostType":2,"repost":{"id":"1183532320","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614957526,"share":"https://ttm.financial/m/news/1183532320?lang=en_US&edition=fundamental","pubTime":"2021-03-05 23:18","market":"us","language":"zh","title":"Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183532320","media":"老虎资讯综合","summary":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.","content":"<p>On Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>It turned up in the intraday session, once rising by more than 10%, and as of press time, it rose by 5.09%. It fell more than 16% at the beginning of the session.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, GSX announced its unaudited financial reports for the fourth quarter of fiscal 2020 and the full year of fiscal 2020. According to the report, GSX's revenue in Q4 2020 reached 2.211 billion yuan, a year-on-year increase of 136.5%, and the number of regular-price courses paid increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report of fiscal year 2020 is the first quarter report card after GSX merged all K12 businesses into \"Gaotu Classroom\". The revenue of K12 online courses was 1.975 billion yuan, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. The cash income of K12 online courses was 2.923 billion yuan, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash income; The number of regular-priced K12 online courses paid reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of all regular-priced courses paid by the company.</p><p>At the same time, as of December 31, 2020, GSX achieved revenue of 7.125 billion yuan in fiscal year 2020, a year-on-year increase of 236.9%, and the number of regular-price courses paid reached 5.871 million, a year-on-year increase of 168.4%. Among them, the revenue of K12 online courses was 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people who paid for regular price courses of K12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of GSX, said: \"In the fourth quarter of 2020, revenue reached a new high, reaching 2.21 billion yuan. In 2020, operating income increased by 236.9% year-on-year to 7.12 billion yuan. GSX achieved such growth rate and scale through efficient operation. In the fourth quarter alone, the operating net cash flow in a single quarter was as high as 636 million yuan, and the annual operating net cash flow continued to be positive.\"</p><p>It is worth noting that on March 2nd this year, GSX announced that the independent investigation on a number of short-selling reports in 2020 had basically ended. According to the investigation results feedback from third-party professional consultants hired by the company's independent audit committee, no evidence of material adverse impact on the company's historical financial statements was found.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Who Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWho Learns open low Goes High to Reverse 16% Decline, Intraday Rise Over 10%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time smaller\">2021-03-05 23:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On Friday,<a href=\"https://laohu8.com/S/GSX\">Who to learn from</a>It turned up in the intraday session, once rising by more than 10%, and as of press time, it rose by 5.09%. It fell more than 16% at the beginning of the session.</p><p><img src=\"https://static.tigerbbs.com/cb6b5d6338311733c563f52359dabb4f\" tg-width=\"840\" tg-height=\"470\"></p><p>On March 5, GSX announced its unaudited financial reports for the fourth quarter of fiscal 2020 and the full year of fiscal 2020. According to the report, GSX's revenue in Q4 2020 reached 2.211 billion yuan, a year-on-year increase of 136.5%, and the number of regular-price courses paid increased by 107.6% year-on-year to 2.275 million.</p><p>The Q4 financial report of fiscal year 2020 is the first quarter report card after GSX merged all K12 businesses into \"Gaotu Classroom\". The revenue of K12 online courses was 1.975 billion yuan, a year-on-year increase of 155.6%, accounting for 89.33% of the company's total revenue. The cash income of K12 online courses was 2.923 billion yuan, a year-on-year increase of 109.8%, accounting for 92.90% of the company's total cash income; The number of regular-priced K12 online courses paid reached 2.139 million, a year-on-year increase of 112.8%, accounting for 94% of all regular-priced courses paid by the company.</p><p>At the same time, as of December 31, 2020, GSX achieved revenue of 7.125 billion yuan in fiscal year 2020, a year-on-year increase of 236.9%, and the number of regular-price courses paid reached 5.871 million, a year-on-year increase of 168.4%. Among them, the revenue of K12 online courses was 6.237 billion yuan, a year-on-year increase of 265.5%, and the number of people who paid for regular price courses of K12 online courses reached 5.429 million, a year-on-year increase of 177.3%.</p><p>Chen Xiangdong, founder, chairman and CEO of GSX, said: \"In the fourth quarter of 2020, revenue reached a new high, reaching 2.21 billion yuan. In 2020, operating income increased by 236.9% year-on-year to 7.12 billion yuan. GSX achieved such growth rate and scale through efficient operation. In the fourth quarter alone, the operating net cash flow in a single quarter was as high as 636 million yuan, and the annual operating net cash flow continued to be positive.\"</p><p>It is worth noting that on March 2nd this year, GSX announced that the independent investigation on a number of short-selling reports in 2020 had basically ended. According to the investigation results feedback from third-party professional consultants hired by the company's independent audit committee, no evidence of material adverse impact on the company's historical financial statements was found.</p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1f49cfbbad938b58f9d764c4f5e672e9","relate_stocks":{"GSX":"Tradr 2X Long GS Daily ETF"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183532320","content_text":"周五，跟谁学盘中转涨，一度涨超10%，截至发稿涨幅5.09%。盘初曾跌超16%。3月5日，跟谁学公布了2020财年第四季度及2020财年全年未经审计财务报告。根据报告，跟谁学2020年Q4收入达22.11亿元，同比增长136.5%，正价课付费人次同比增长107.6%达227.5万。2020财年Q4财报是跟谁学将K12业务全部合并至“高途课堂”后的首季成绩单，K12在线课程收入为19.75亿元，同比增长155.6%，占公司全部收入的89.33%，K12在线课程的现金收入为29.23亿元人民币，同比增长109.8%,，占公司全部现金收入的92.90%；K12在线课程正价课付费人次达到213.9万，同比增长112.8%，占公司全部正价课付费人次的94%。同时，截止到2020年12月31日，跟谁学2020财年全年实现收入71.25亿元，同比增长236.9%，正价课付费人次达587.1万，同比增长168.4%。其中，K12 在线课程收入为62.37亿元，同比增长265.5%，K12在线课程正价课付费人次达542.9万，同比增长177.3%。跟谁学创始人、董事长兼CEO陈向东表示：“2020年第四季度收入创造新高，达到22.1亿元。2020年营业收入同比增长了236.9%，为71.2亿元。跟谁学取得这样的增速和规模是通过高效率的运营达成的，仅第四季度单季经营净现金流就高达6.36亿元，全年经营净现金流也持续为正”。值得关注的是，今年3月2日，跟谁学发布公告称，针对2020年多份做空报告开展的独立调查已基本结束，根据公司独立审计委员会聘请的第三方专业顾问反馈的调查结果，没有发现对公司历史财务报表有重大不利影响的证据。","news_type":1,"symbols_score_info":{"GSX":0.9}},"isVote":1,"tweetType":1,"viewCount":2402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811218252,"gmtCreate":1630326149476,"gmtModify":1676530269198,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811218252","repostId":"2163012390","repostType":2,"repost":{"id":"2163012390","kind":"news","pubTimestamp":1630308776,"share":"https://ttm.financial/m/news/2163012390?lang=en_US&edition=fundamental","pubTime":"2021-08-30 15:32","market":"hk","language":"zh","title":"UBS: Give WuXi Biologics (02269) a \"Buy\" rating with a price target of HK$142","url":"https://stock-news.laohu8.com/highlight/detail?id=2163012390","media":"智通财经","summary":"智通财经APP获悉，瑞银发布研究报告称，予药明生物“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。","content":"<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/UBS\">UBS</a>Published a study report stating that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) with a \"Buy\" rating and a target price of HK$142, raised its 2021-23 earnings per share forecast by 26% to 38% to reflect stronger-than-expected pandemic and CMO-related projects, and raised its 2020-24 revenue forecast by 11% to reflect stronger-than-expected growth in COVID-19 projects and pharmaceutical manufacturing outsourcing (CMO) growth.</p><p>According to the report, according to the management, there will be at least four to five non-COVID-19-related CMOs before the end of 2022, which is estimated to drive the company's long-term profit growth. The management will maintain the 2021 guidance, and it is expected that the revenue and net profit will increase by 65% year-on-year. The bank believes that if the growth is not affected by supply shortage, the company is expected to outperform the guidance.</p><p>According to the bank, according to the management, there is no evidence that the U.S. government will restrict U.S. companies from using CDMO companies based in China. At the same time, 20% of WuXi customers have considered using the company's production capacity in Europe and the United States to reduce risks. Considering the nature of the company's CDMO services, if drugs are produced in Europe and the United States and shipped there, they will not be regarded as exported from China to the United States, which is believed to reduce the risk of unstable drug supply.</p><p></body></html></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS: Give WuXi Biologics (02269) a \"Buy\" rating with a price target of HK$142</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS: Give WuXi Biologics (02269) a \"Buy\" rating with a price target of HK$142\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-30 15:32</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/UBS\">UBS</a>Published a study report stating that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) with a \"Buy\" rating and a target price of HK$142, raised its 2021-23 earnings per share forecast by 26% to 38% to reflect stronger-than-expected pandemic and CMO-related projects, and raised its 2020-24 revenue forecast by 11% to reflect stronger-than-expected growth in COVID-19 projects and pharmaceutical manufacturing outsourcing (CMO) growth.</p><p>According to the report, according to the management, there will be at least four to five non-COVID-19-related CMOs before the end of 2022, which is estimated to drive the company's long-term profit growth. The management will maintain the 2021 guidance, and it is expected that the revenue and net profit will increase by 65% year-on-year. The bank believes that if the growth is not affected by supply shortage, the company is expected to outperform the guidance.</p><p>According to the bank, according to the management, there is no evidence that the U.S. government will restrict U.S. companies from using CDMO companies based in China. At the same time, 20% of WuXi customers have considered using the company's production capacity in Europe and the United States to reduce risks. Considering the nature of the company's CDMO services, if drugs are produced in Europe and the United States and shipped there, they will not be regarded as exported from China to the United States, which is believed to reduce the risk of unstable drug supply.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/549312.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f874ded00c644297784368a7af94c8ae","relate_stocks":{"02269":"药明生物"},"source_url":"http://www.zhitongcaijing.com/content/detail/549312.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163012390","content_text":"智通财经APP获悉，瑞银发布研究报告称，予药明生物(02269)“买入”评级，目标价142港元，将2021-23年每股盈测升26%至38%，以反映疫情及CMO相关项目强过预期，并将2020-24收入预测升11%，以反映新冠项目增长强过预期及及药物生产外包(CMO)增长。报告中称，据管理层指出在2022年底前将有最少四至五项非新冠病毒相关的CMO，估计将带动公司长远盈利增长，管理层将维持2021年指引，预计收入、净利将同比增长65%，该行相信假如增长不受供应短缺影响，公司有望跑赢指引。该行表示，据管理层指，现时未有证据美国政府将限制美国企业使用以中国为基地的CDMO企业，同时有20%药明的客户已考虑使用公司于欧美的产能以减低风险，考虑公司CDMO服务性质，假如药物于欧美生产并运往当地，将不被视作由中国出口至美国，相信可减低药物供应不稳的风险。","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":2678,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835151166,"gmtCreate":1629696705355,"gmtModify":1676530102959,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/835151166","repostId":"2161725272","repostType":2,"repost":{"id":"2161725272","kind":"news","pubTimestamp":1629684392,"share":"https://ttm.financial/m/news/2161725272?lang=en_US&edition=fundamental","pubTime":"2021-08-23 10:06","market":"us","language":"zh","title":"[Moving stocks] WuXi Biologics (02269.HK) rose 3.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2161725272","media":"金融界网站","summary":"【财华社讯】药明生物(02269.HK)截至10:06上涨3.13%，现报108.6港元，涨3.3港元。成交375万股，涉资3.967亿元。（出处：FinetAI）","content":"<p><html><body><div>[Caihua News]<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269.HK) rose 3.13% as of 10:06 and is now traded at HK$108.6, up HK$3.3. 3.75 million shares were traded, involving 396.7 million yuan. (Source: FinetAI)</p><p><div></div></div></body></html></p>","source":"jinrongjie_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>[Moving stocks] WuXi Biologics (02269.HK) rose 3.13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n[Moving stocks] WuXi Biologics (02269.HK) rose 3.13%\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">金融界网站</strong><span class=\"h-time small\">2021-08-23 10:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div>[Caihua News]<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269.HK) rose 3.13% as of 10:06 and is now traded at HK$108.6, up HK$3.3. 3.75 million shares were traded, involving 396.7 million yuan. (Source: FinetAI)</p><p><div></div></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://hk.jrj.com.cn/2021/08/23100633301119.shtml\">金融界网站</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","relate_stocks":{"02269":"药明生物"},"source_url":"http://hk.jrj.com.cn/2021/08/23100633301119.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161725272","content_text":"【财华社讯】药明生物(02269.HK)截至10:06上涨3.13%，现报108.6港元，涨3.3港元。成交375万股，涉资3.967亿元。（出处：FinetAI）","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":3315,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811103906,"gmtCreate":1630293590105,"gmtModify":1676530259718,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811103906","repostId":"2163702540","repostType":2,"repost":{"id":"2163702540","kind":"news","pubTimestamp":1630285168,"share":"https://ttm.financial/m/news/2163702540?lang=en_US&edition=fundamental","pubTime":"2021-08-30 08:59","market":"us","language":"zh","title":"Business two-wheel drive improved strategic layout, Jingneng Clean Energy (0579.HK) interim results steadily improved","url":"https://stock-news.laohu8.com/highlight/detail?id=2163702540","media":"格隆汇","summary":"总结来说，整个2021年上半年，京能清洁能源凭借其自身的软硬实力，充分发挥多元化的竞争优势，使得各个业务板块实现稳健增长。","content":"<p><html><body><span>On August 26, Hong Kong stocks<a href=\"https://laohu8.com/S/00579\">Jingneng Clean Energy</a>(0579.HK) announced its 2021 interim results report: achieved operating income of RMB9.340 billion, representing a year-on-year increase of 12.81%; Profit before tax was RMB1,884 million, representing a year-on-year increase of 13.90%; Profit attributable to ordinary shareholders of the Company was RMB1,488 million, representing a year-on-year increase of 14.90%; Basic and diluted earnings per share were RMB18.05 cents.</span></p><p>This is an excellent report card. In the fiercely competitive market environment, in the first half of this year, the year-on-year growth rate of revenue and net profit of Jingneng Clean Energy both achieved double-digit growth. It can be said that there is progress in \"stability\" and full momentum for progress.</p><p><b><font color=\"#ff0000\">Steady business growth and further consolidation of industry position</font></b></p><p>Through the semi-annual performance report released by Jingneng Clean Energy, it can be found that while the operating performance has grown steadily, it has performed well in many business dimensions and has been continuously optimized.</p><p><b>The installed capacity has steadily increased,</b>As of June 30, 2021, the total installed capacity of the Company was 11.215 million kilowatts, representing a year-on-year increase of 14%, of which, the newly installed capacity of the wind power business segment was 349,000 kilowatts, all of which came from self-built projects.</p><p><b>The power generation showed a large increase.</b>As of June 30, 2021, the total power generation of the Company's holding was 16.179 billion kWh, representing a year-on-year increase of 17.73%.</p><p>Among which, the power generation of gas-fired power generation and heating business segment increased by 8.08% year-on-year;<b>The power generation of wind power business segment increased by 44.43% year-on-year; The power generation of photovoltaic power generation business segment increased by 37.87% year-on-year, significantly higher than the national industry level in the same period.</b></p><p><b>In summary,</b>Throughout the first half of 2021, Jingneng Clean Energy leveraged on its own soft and hard strengths and fully leveraged its diversified competitive advantages to achieve steady growth in various business segments.</p><p>In particular, the photovoltaic sector has exceeded the national level in the same period, fully catering to the development concepts of \"30,60\" and \"carbon peak and carbon neutrality\", further consolidating the company's industry leading position as a local new energy state-owned enterprise.</p><p><b><font color=\"#ff0000\">2. Independent development and project mergers and acquisitions are driven by two wheels, and the business synergy is highlighted</font></b></p><p>When judging the growth of an enterprise, there are often two points worth paying attention to. First, the growth of endogenous power depends on the accumulation of the enterprise itself; Second, extension mergers and acquisitions, through mergers and acquisitions, realize the integration of markets, resources and technologies, and achieve rapid development under the efficient internal control ability of enterprises.</p><p><b>In terms of the growth of endogenous power, the Group continued to accelerate the development and construction of independent projects.</b>According to the data of the interim report, as of the first half of 2021, the company independently developed 18 wind power and photovoltaic projects with construction indicators, with an installed capacity of 1.754 million kilowatts.</p><p>Among them, the \"Beijing-Zhangjiakou Olympic Wind Power Project\" undertaken by the company takes advantage of the abundant wind power resources in Zhangjiakou area and takes the opportunity of Beijing and Hebei Province's joint bid to host the Winter Olympic Committee to transmit the wind power in Zhangjiakou area to Beijing power grid for consumption by winter heating, and at the same time contributes to the pioneering initiative of 2022 Beijing Winter Olympic Committee to realize green power coverage in all venues for the first time in Olympic history.</p><p>Not only that, the construction of this project has enabled the development and utilization of abundant local wind energy resources, which has played a huge role in promoting the development of regional economy. At the same time, it has greatly optimized Beijing's energy structure, which is more conducive to the strategic deployment of the coordinated development of the central government's \"Beijing-Tianjin-Hebei integration\" and produces practical results.</p><p>It is understood that the total installed capacity of the project is 1.2 million kilowatts. Among them, Jingneng Clean Energy has a self-built capacity of 775,000 kilowatts. Up to now, the share transfer of Dongxu Shangyi 200,000 kilowatts wind power project and Guoxin Haojiaying 100,000 kilowatts wind power project has been completed. The installed capacity of Jingneng's clean energy management reaches 1.075 million kilowatts, and the total investment of the project is about 9 billion yuan.</p><p><b>In terms of extension expansion, we will vigorously expand our business through project mergers and acquisitions. As of the first half of 2021,</b>There are 13 wind power and photovoltaic projects under merger and acquisition, with an installed capacity of 1.486 million kilowatts. In July this year, the company entered into an equity transfer agreement between Kaiyang and Boyang with Ningxia Jiaze, and acquired 297.5MW wind power and photovoltaic project in Ningxia Hongsibao and 99MW wind power project in Ningxia Tongxin, which contributed to the installed capacity growth of Jingneng Clean Energy in the second half of the year.</p><p>It is worth mentioning that,<b>This acquisition is conducive to the intensive management of Jingneng Clean Energy Northwest Branch, and will form a good synergy effect with the company's existing assets. It can not only achieve the purpose of complementing each other's advantages, learning from each other's strengths, reducing costs and increasing efficiency, and coordinating businesses with each other, but also enable the company to form a nationwide and all-round strategic layout.</b></p><p><b>In fact, acquisitions and acquisitions are the only way to enhance the concentration of the new energy industry, and it is also a manifestation of the internal reshuffle of the industry.</b>With the increase of the cost of self-built projects in the overall industry, it has become one of the new business models of new energy enterprises to seek to acquire equity through mergers and acquisitions, and even acquire other industries to fill the shortcomings of business layout and expand the scale.</p><p>For new energy enterprises, changing from pure competition to cooperation can not only borrow from each other, but also avoid investment risks to a certain extent and maximize benefits. At the same time, we can also give full play to the strengths of each company and make the enterprise the best.</p><p>Therefore, in the long run, with the changes of the market environment, the future development model of new energy enterprises will not only practice hard and strengthen their own hard-core strength, but also obtain more resources in the form of mergers and acquisitions, reorganizations, etc., and try in many fields. \"Two-wheel drive\" and even \"four-wheel drive\" will be the future growth road of new energy enterprises. Jingneng Clean Energy has officially embarked on this high-speed road of \"becoming stronger and bigger\".</p><p></body></html></p>","source":"stock_gelonghui","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Business two-wheel drive improved strategic layout, Jingneng Clean Energy (0579.HK) interim results steadily improved</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBusiness two-wheel drive improved strategic layout, Jingneng Clean Energy (0579.HK) interim results steadily improved\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">格隆汇</strong><span class=\"h-time small\">2021-08-30 08:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><span>On August 26, Hong Kong stocks<a href=\"https://laohu8.com/S/00579\">Jingneng Clean Energy</a>(0579.HK) announced its 2021 interim results report: achieved operating income of RMB9.340 billion, representing a year-on-year increase of 12.81%; Profit before tax was RMB1,884 million, representing a year-on-year increase of 13.90%; Profit attributable to ordinary shareholders of the Company was RMB1,488 million, representing a year-on-year increase of 14.90%; Basic and diluted earnings per share were RMB18.05 cents.</span></p><p>This is an excellent report card. In the fiercely competitive market environment, in the first half of this year, the year-on-year growth rate of revenue and net profit of Jingneng Clean Energy both achieved double-digit growth. It can be said that there is progress in \"stability\" and full momentum for progress.</p><p><b><font color=\"#ff0000\">Steady business growth and further consolidation of industry position</font></b></p><p>Through the semi-annual performance report released by Jingneng Clean Energy, it can be found that while the operating performance has grown steadily, it has performed well in many business dimensions and has been continuously optimized.</p><p><b>The installed capacity has steadily increased,</b>As of June 30, 2021, the total installed capacity of the Company was 11.215 million kilowatts, representing a year-on-year increase of 14%, of which, the newly installed capacity of the wind power business segment was 349,000 kilowatts, all of which came from self-built projects.</p><p><b>The power generation showed a large increase.</b>As of June 30, 2021, the total power generation of the Company's holding was 16.179 billion kWh, representing a year-on-year increase of 17.73%.</p><p>Among which, the power generation of gas-fired power generation and heating business segment increased by 8.08% year-on-year;<b>The power generation of wind power business segment increased by 44.43% year-on-year; The power generation of photovoltaic power generation business segment increased by 37.87% year-on-year, significantly higher than the national industry level in the same period.</b></p><p><b>In summary,</b>Throughout the first half of 2021, Jingneng Clean Energy leveraged on its own soft and hard strengths and fully leveraged its diversified competitive advantages to achieve steady growth in various business segments.</p><p>In particular, the photovoltaic sector has exceeded the national level in the same period, fully catering to the development concepts of \"30,60\" and \"carbon peak and carbon neutrality\", further consolidating the company's industry leading position as a local new energy state-owned enterprise.</p><p><b><font color=\"#ff0000\">2. Independent development and project mergers and acquisitions are driven by two wheels, and the business synergy is highlighted</font></b></p><p>When judging the growth of an enterprise, there are often two points worth paying attention to. First, the growth of endogenous power depends on the accumulation of the enterprise itself; Second, extension mergers and acquisitions, through mergers and acquisitions, realize the integration of markets, resources and technologies, and achieve rapid development under the efficient internal control ability of enterprises.</p><p><b>In terms of the growth of endogenous power, the Group continued to accelerate the development and construction of independent projects.</b>According to the data of the interim report, as of the first half of 2021, the company independently developed 18 wind power and photovoltaic projects with construction indicators, with an installed capacity of 1.754 million kilowatts.</p><p>Among them, the \"Beijing-Zhangjiakou Olympic Wind Power Project\" undertaken by the company takes advantage of the abundant wind power resources in Zhangjiakou area and takes the opportunity of Beijing and Hebei Province's joint bid to host the Winter Olympic Committee to transmit the wind power in Zhangjiakou area to Beijing power grid for consumption by winter heating, and at the same time contributes to the pioneering initiative of 2022 Beijing Winter Olympic Committee to realize green power coverage in all venues for the first time in Olympic history.</p><p>Not only that, the construction of this project has enabled the development and utilization of abundant local wind energy resources, which has played a huge role in promoting the development of regional economy. At the same time, it has greatly optimized Beijing's energy structure, which is more conducive to the strategic deployment of the coordinated development of the central government's \"Beijing-Tianjin-Hebei integration\" and produces practical results.</p><p>It is understood that the total installed capacity of the project is 1.2 million kilowatts. Among them, Jingneng Clean Energy has a self-built capacity of 775,000 kilowatts. Up to now, the share transfer of Dongxu Shangyi 200,000 kilowatts wind power project and Guoxin Haojiaying 100,000 kilowatts wind power project has been completed. The installed capacity of Jingneng's clean energy management reaches 1.075 million kilowatts, and the total investment of the project is about 9 billion yuan.</p><p><b>In terms of extension expansion, we will vigorously expand our business through project mergers and acquisitions. As of the first half of 2021,</b>There are 13 wind power and photovoltaic projects under merger and acquisition, with an installed capacity of 1.486 million kilowatts. In July this year, the company entered into an equity transfer agreement between Kaiyang and Boyang with Ningxia Jiaze, and acquired 297.5MW wind power and photovoltaic project in Ningxia Hongsibao and 99MW wind power project in Ningxia Tongxin, which contributed to the installed capacity growth of Jingneng Clean Energy in the second half of the year.</p><p>It is worth mentioning that,<b>This acquisition is conducive to the intensive management of Jingneng Clean Energy Northwest Branch, and will form a good synergy effect with the company's existing assets. It can not only achieve the purpose of complementing each other's advantages, learning from each other's strengths, reducing costs and increasing efficiency, and coordinating businesses with each other, but also enable the company to form a nationwide and all-round strategic layout.</b></p><p><b>In fact, acquisitions and acquisitions are the only way to enhance the concentration of the new energy industry, and it is also a manifestation of the internal reshuffle of the industry.</b>With the increase of the cost of self-built projects in the overall industry, it has become one of the new business models of new energy enterprises to seek to acquire equity through mergers and acquisitions, and even acquire other industries to fill the shortcomings of business layout and expand the scale.</p><p>For new energy enterprises, changing from pure competition to cooperation can not only borrow from each other, but also avoid investment risks to a certain extent and maximize benefits. At the same time, we can also give full play to the strengths of each company and make the enterprise the best.</p><p>Therefore, in the long run, with the changes of the market environment, the future development model of new energy enterprises will not only practice hard and strengthen their own hard-core strength, but also obtain more resources in the form of mergers and acquisitions, reorganizations, etc., and try in many fields. \"Two-wheel drive\" and even \"four-wheel drive\" will be the future growth road of new energy enterprises. Jingneng Clean Energy has officially embarked on this high-speed road of \"becoming stronger and bigger\".</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"https://www.gelonghui.com/news/detail.html?id=608034\">格隆汇</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/f01e4b782ba393cb7794f7764a5d7d90","relate_stocks":{"00579":"京能清洁能源"},"source_url":"https://www.gelonghui.com/news/detail.html?id=608034","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163702540","content_text":"8月26日，港股京能清洁能源(0579.HK)公布2021中期业绩报告：实现营业收入人民币93.40亿元，同比增长12.81%；除税前溢利为人民币18.84亿元，同比增长13.90%；公司普通股股东应占溢利为人民币14.88亿元，同比增长14.90%；每股基本及摊薄盈利人民币18.05分。这是一份优异的成绩单，在竞争激烈的市场环境下，今年上半年，京能清洁能源的营收、净利润同比增速双双取得两位数增长，可以说“稳”中有进，前进动力十足。1、业务稳健增长，行业地位进一步巩固通过京能清洁能源发布的半年度业绩报告，可以发现在经营业绩稳健增长的同时，在多个业务维度均有不俗表现，并且得到持续优化。装机容量稳步提高，截至2021年6月30日，公司控股总装机容量为1,121.5万千瓦，同比增长14%，其中，风力发电业务板块新增装机容量34.9万千瓦，全部来自于自建项目。发电量呈现较大幅度的增长。截至2021年6月30日，公司控股总发电量为161.79亿千瓦时，同比增长17.73%。其中燃气发电及供热业务板块发电量同比增长8.08%；风力发电业务板块发电量同比增长44.43%；光伏发电业务板块发电量同比增长37.87%，明显高于全国行业同期水平。总结来说，整个2021年上半年，京能清洁能源凭借其自身的软硬实力，充分发挥多元化的竞争优势，使得各个业务板块实现稳健增长。尤其是光伏板块更是超过全国同期的水平，充分迎合“30,60”、“碳达峰、碳中和”的发展理念，进一步巩固了公司作为地方新能源国企的行业领先地位。2、自主开发与项目并购双轮驱动，业务协同效应凸显评判一家企业的增长，往往有两个看点值得关注，其一，内生动力的增长，即依靠企业自身积累，厚积薄发；其二，外延式并购，通过收并购，实现市场、资源、技术的整合，在高效的企业内控能力之下，实现高速发展。 在内生动力增长方面，不断加快自主项目开发、建设的步伐。根据中报数据显示，截至2021年上半年，公司自主开发取得建设指标的风电、光伏项目18个，装机容量175.4万千瓦。 其中，公司承建的“京张奥运风电项目”，利用张家口地区丰富的风电资源，以北京市和河北省联合申办冬奥委会为契机，将张家口地区风电输送至北京电网以冬季供热方式进行消纳，同时为2022年北京冬奥委会在奥运史上首次实现全部场馆绿色电力覆盖的创举贡献首都国企的一份力量。不仅如此，该项目的建设让当地丰富的风能资源得到了开发与利用，对发展地区经济起到巨大的推动作用。同时极大地优化了北京能源结构，更有利于中央“京津冀一体化”协同发展的战略部署落地、产生实效。据了解，该项目总装机容量120万千瓦。其中京能清洁能源自建容量77.5万千瓦，截至目前，已经完成了东旭尚义20万千瓦风电项目、国新郝家营10万千瓦风电项目股转。京能清洁能源管理装机容量达107.5万千瓦，项目总投资约90亿元。在外延式扩张上，通过项目并购的方式大力拓展业务。截至2021年上半年，正在开展并购工作的风电、光伏项目共计13个，装机容量148.6万千瓦。今年7月份，公司与宁夏嘉泽订立了恺阳及博阳股权转让协议，收购了宁夏红寺堡297.5MW风电、光伏项目及宁夏同心99MW风电项目，为京能清洁能源下半年的装机容量增长贡献了一份力量。值得一提的是，此次收购有利于京能清洁能源西北分公司的集约化管理，将与公司既有资产形成较好的协同效应。不仅可以达到优势互补，取长补短，降本增效，业务相互协同的目的，还可以让公司形成全国化、全方位的战略布局。事实上，收购并购是新能源行业集中度增强的必经之路，也是行业内部洗牌的一种表现。随着整体行业自建项目成本的增加，寻求通过并购形式收购股权获得项目，甚至收购其他行业填补业态布局短板、扩大规模已成为新能源企业新的经营模式之一。对新能源企业而言，由之前的纯竞争转为合作，不仅可以相互借力，一定程度上规避投资风险，实现利益最大化。同时，还可以发挥各家所长，把企业做到最好。因此，长期来看，随着市场环境的变化，新能源企业未来的发展模式，除了苦练内功，增强自身的硬核实力之外，以并购、重组等形式来获取更多资源，多领域的尝试，“双轮驱动”以至“四轮驱动”将是新能源的企业未来成长之路，京能清洁能源已正式踏上了这条“做强、做大”的高速之路。","news_type":1,"symbols_score_info":{"00579":1}},"isVote":1,"tweetType":1,"viewCount":3567,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811109949,"gmtCreate":1630293486281,"gmtModify":1676530259693,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811109949","repostId":"1167910924","repostType":2,"isVote":1,"tweetType":1,"viewCount":3007,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810814571,"gmtCreate":1629962150993,"gmtModify":1676530185284,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810814571","repostId":"2162106440","repostType":2,"repost":{"id":"2162106440","kind":"news","pubTimestamp":1629959831,"share":"https://ttm.financial/m/news/2162106440?lang=en_US&edition=fundamental","pubTime":"2021-08-26 14:37","market":"sh","language":"zh","title":"Morgan Stanley: Give WuXi Biologics an \"overweight\" rating, the target price rose 3.6% to HK$170","url":"https://stock-news.laohu8.com/highlight/detail?id=2162106440","media":"智通财经","summary":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。 ...","content":"<p><html><body><div>Morgan Stanley released a research report saying that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Overweight\" rating, the target price was raised from HK$164 to HK$170, and the earnings forecast for 2021-24 was raised by 1% to 9% to reflect the strong first half performance, and the revenue and gross profit forecast were also raised simultaneously.</p><p><strong>follow<a href=\"https://laohu8.com/S/300033\">Flush</a>Finance (ths518), Get More Opportunities</strong></p><p><span></span><div><span>Editor in Charge: cjh</span></div></div></body></html></p>","source":"tonghuashun","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley: Give WuXi Biologics an \"overweight\" rating, the target price rose 3.6% to HK$170</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley: Give WuXi Biologics an \"overweight\" rating, the target price rose 3.6% to HK$170\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-26 14:37</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body><div>Morgan Stanley released a research report saying that<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Overweight\" rating, the target price was raised from HK$164 to HK$170, and the earnings forecast for 2021-24 was raised by 1% to 9% to reflect the strong first half performance, and the revenue and gross profit forecast were also raised simultaneously.</p><p><strong>follow<a href=\"https://laohu8.com/S/300033\">Flush</a>Finance (ths518), Get More Opportunities</strong></p><p><span></span><div><span>Editor in Charge: cjh</span></div></div></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/24fa8350588843d92f819ac12ab5ce16","relate_stocks":{"02269":"药明生物"},"source_url":"http://stock.10jqka.com.cn/hks/20210826/c632175865.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/f0343184bd9b9c963ed02b302442e2b8","article_id":"2162106440","content_text":"大摩发布研究报告称，予药明生物(02269)“增持”评级，目标价自164港元上调至170港元，上调2021-24年间盈测1%至9%，以反映强劲上半年业绩表现，收入及毛利润预测也同步上调。\n关注同花顺财经（ths518），获取更多机会\n\n责任编辑：cjh","news_type":1,"symbols_score_info":{"02269":1}},"isVote":1,"tweetType":1,"viewCount":2811,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837654134,"gmtCreate":1629886521628,"gmtModify":1676530162487,"author":{"id":"3550828792714737","authorId":"3550828792714737","name":"记事本2020","avatar":"https://static.tigerbbs.com/f529f483c65820f1fbdbed82968cd4d7","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3550828792714737","idStr":"3550828792714737"},"themes":[],"title":"","htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837654134","repostId":"2162031026","repostType":2,"repost":{"id":"2162031026","kind":"news","pubTimestamp":1629875170,"share":"https://ttm.financial/m/news/2162031026?lang=en_US&edition=fundamental","pubTime":"2021-08-25 15:06","market":"hk","language":"zh","title":"Zhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments","url":"https://stock-news.laohu8.com/highlight/detail?id=2162031026","media":"智通财经","summary":"智通财经APP获悉，中泰证券发布研究报告称，维持药明生物“买入”评级，认为公司是全球生物药外包服务行业稀缺标的，所处行业高景气、公司优势凸显，后续随着现有项目进入商业化，以及XDC、疫苗、双抗等平台加速兑现，长期空间广阔，未来可期。中泰证券主要观点如下：业绩超预期，归母净利润高于业绩预告。前次业绩预告2021H1归母净利润同比增长135%，实际增长150.3%，高于预期。","content":"<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/600918\">Zhongtai Securities</a>Released a research report saying that maintaining<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Buy\" rating, believing that the company is a scarce target in the global biopharmaceutical outsourcing service industry, with high prosperity in the industry and prominent advantages of the company. Subsequently, with the commercialization of existing projects, XDC, vaccines, double antibodies and other platforms to accelerate the realization, the long-term space is broad, and the future is promising.</p><p><strong>Event:</strong>The company released its results for the first half of 2021, and achieved operating income of 4.41 billion yuan during the period, representing a year-on-year increase of 126.7%; Net profit attributable to the parent was 1.84 billion yuan, a year-on-year increase of 150.3%; The adjusted net profit attributable to the parent was 1.77 billion yuan, a year-on-year increase of 163%.</p><p><strong>The main views of Zhongtai Securities are as follows:</strong></p><p><strong>The performance exceeded expectations, and the net profit attributable to the parent was higher than the performance forecast.</strong></p><p>The previous performance forecast 2021H1 net profit attributable to the parent increased by 135% year-on-year, and the actual growth was 150.3%, which was higher than expected. The Bank believes that it is mainly due to:</p><p>1) The volume of late clinical and commercialization projects increased rapidly, including the clinical stage revenue of 1.94 billion yuan (+109.2% year-on-year) and the commercialization stage revenue of 889 million yuan (+2923.5%);</p><p>2) the rapid recovery of demand after the normalization of overseas epidemic, with revenue from North America of RMB2.19 billion (+149.3% year-on-year) and revenue from Europe of RMB990 million (+706.8% year-on-year) in 2021H1;</p><p>3) continuous optimization of management capabilities and continuous improvement of operational efficiency, with gross profit margin of approximately 52.1% (+11.6pp), net profit margin of approximately 41.8% (+3.9pp) and period expense ratio of approximately 12.4% (-8.2pp) in 2021H1;</p><p>4) Low base last year: In the first half of last year, the overall base was low due to the epidemic disturbance, with 740 million (+63.6%) attributable to the parent in 2020H1. However, compared with the net profit attributable to the parent in 2019H1, the company's CAGR from 2019H1 to 2021H1 was about 102.3%, with a rapid growth.</p><p><strong>CMO's logic of heavy volume continues to be realized, and the strategy of following and winning molecules is progressing smoothly, which is expected to accelerate the growth of overall performance.</strong></p><p>Adhering to the strategy of following and winning molecules, as of June 30, the company extended 27 projects (14 pre-clinical to clinical, 2 phase III to commercial) in the first half of the year, introduced 20 clinical projects externally (+400%, including 9 clinical phase II and 4 clinical phase III), added 79 projects, and the overall number of projects reached 408 (+42.7% year-on-year compared with 2020H1), including 212 pre-clinical (+50.4%), 160 early (phase I and phase II) projects (+28%), 32 phase III projects (+68.4%), and 4 commercial projects (three new).</p><p>In addition, due to the rapid growth of the number of projects, the company's orders in hand continue to increase rapidly. It is expected that in the next three years, the total amount of orders completed will reach 2.25 billion USD (+143.1%), and the total amount of uncompleted orders will be about 12.46 billion USD (+31.7%), of which the outstanding service orders will be 7.23 billion USD (+25.2%). It is expected that the bank will have seven commercialization projects in 2021, which is expected to promote a new round of heavy volume in the CDMO sector and accelerate the overall performance growth.</p><p><strong>Advanced XDC, vaccine and dual antibody platforms bring new growth momentum.</strong></p><p><strong>XDC:</strong>The company's XDC drug R&D platform has undertaken 48 ADC projects (+60%) with the advantages of WuXiDAR4 technology, and 15 CDMO projects are already underway, and the commercialization volume can be expected;</p><p><strong>WuxiVaccine:</strong>Nine vaccine orders are being executed (up 8 year-on-year), and the orders in hand have increased to US$3.3 billion. WuXi Haide is expected to be put into operation in 2022, which is expected to continue to bring incremental performance.</p><p><strong>Double antibody:</strong>WuxiBody ™ Undertake 31 projects (+19.2%), and expect to add 1~2 IND applications in 2021, which is expected to extend CDMO to gradually contribute new increments.</p><p><strong>Earnings Forecast and Investment Advice:</strong>The bank estimates that the company's revenue from 2021 to 2023 will be 9.36, 13.84 and 19.4 billion yuan, representing a year-on-year increase of 66.7%, 47.9% and 40.2%, and the net profit attributable to the parent will be 2.82, 4.17 and 5.88 billion yuan, representing a year-on-year increase of 67.1%, 47.6% and 41.2%, corresponding to EPS of 0.67, 0.98 and 1.39 yuan.</p><p><strong>Risk warning events:</strong>The public information used in the research report may be subject to the risk of information lag or updating in a timely manner, proposed acquisition<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>The risks of the progress of China's biologics production base project being less than expected, the investment in biologics research and development being less than expected, and the risk of loss of core technical personnel.</p><p></body></html></p>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhongtai Securities: Maintain the \"Buy\" rating of WuXi Biologics (02269) and expect new technology platforms to gradually contribute new increments\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2021-08-25 15:06</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><body>Zhitong Finance APP learned that,<a href=\"https://laohu8.com/S/600918\">Zhongtai Securities</a>Released a research report saying that maintaining<a href=\"https://laohu8.com/S/02269\">WuXi Biologics</a>(02269) \"Buy\" rating, believing that the company is a scarce target in the global biopharmaceutical outsourcing service industry, with high prosperity in the industry and prominent advantages of the company. Subsequently, with the commercialization of existing projects, XDC, vaccines, double antibodies and other platforms to accelerate the realization, the long-term space is broad, and the future is promising.</p><p><strong>Event:</strong>The company released its results for the first half of 2021, and achieved operating income of 4.41 billion yuan during the period, representing a year-on-year increase of 126.7%; Net profit attributable to the parent was 1.84 billion yuan, a year-on-year increase of 150.3%; The adjusted net profit attributable to the parent was 1.77 billion yuan, a year-on-year increase of 163%.</p><p><strong>The main views of Zhongtai Securities are as follows:</strong></p><p><strong>The performance exceeded expectations, and the net profit attributable to the parent was higher than the performance forecast.</strong></p><p>The previous performance forecast 2021H1 net profit attributable to the parent increased by 135% year-on-year, and the actual growth was 150.3%, which was higher than expected. The Bank believes that it is mainly due to:</p><p>1) The volume of late clinical and commercialization projects increased rapidly, including the clinical stage revenue of 1.94 billion yuan (+109.2% year-on-year) and the commercialization stage revenue of 889 million yuan (+2923.5%);</p><p>2) the rapid recovery of demand after the normalization of overseas epidemic, with revenue from North America of RMB2.19 billion (+149.3% year-on-year) and revenue from Europe of RMB990 million (+706.8% year-on-year) in 2021H1;</p><p>3) continuous optimization of management capabilities and continuous improvement of operational efficiency, with gross profit margin of approximately 52.1% (+11.6pp), net profit margin of approximately 41.8% (+3.9pp) and period expense ratio of approximately 12.4% (-8.2pp) in 2021H1;</p><p>4) Low base last year: In the first half of last year, the overall base was low due to the epidemic disturbance, with 740 million (+63.6%) attributable to the parent in 2020H1. However, compared with the net profit attributable to the parent in 2019H1, the company's CAGR from 2019H1 to 2021H1 was about 102.3%, with a rapid growth.</p><p><strong>CMO's logic of heavy volume continues to be realized, and the strategy of following and winning molecules is progressing smoothly, which is expected to accelerate the growth of overall performance.</strong></p><p>Adhering to the strategy of following and winning molecules, as of June 30, the company extended 27 projects (14 pre-clinical to clinical, 2 phase III to commercial) in the first half of the year, introduced 20 clinical projects externally (+400%, including 9 clinical phase II and 4 clinical phase III), added 79 projects, and the overall number of projects reached 408 (+42.7% year-on-year compared with 2020H1), including 212 pre-clinical (+50.4%), 160 early (phase I and phase II) projects (+28%), 32 phase III projects (+68.4%), and 4 commercial projects (three new).</p><p>In addition, due to the rapid growth of the number of projects, the company's orders in hand continue to increase rapidly. It is expected that in the next three years, the total amount of orders completed will reach 2.25 billion USD (+143.1%), and the total amount of uncompleted orders will be about 12.46 billion USD (+31.7%), of which the outstanding service orders will be 7.23 billion USD (+25.2%). It is expected that the bank will have seven commercialization projects in 2021, which is expected to promote a new round of heavy volume in the CDMO sector and accelerate the overall performance growth.</p><p><strong>Advanced XDC, vaccine and dual antibody platforms bring new growth momentum.</strong></p><p><strong>XDC:</strong>The company's XDC drug R&D platform has undertaken 48 ADC projects (+60%) with the advantages of WuXiDAR4 technology, and 15 CDMO projects are already underway, and the commercialization volume can be expected;</p><p><strong>WuxiVaccine:</strong>Nine vaccine orders are being executed (up 8 year-on-year), and the orders in hand have increased to US$3.3 billion. WuXi Haide is expected to be put into operation in 2022, which is expected to continue to bring incremental performance.</p><p><strong>Double antibody:</strong>WuxiBody ™ Undertake 31 projects (+19.2%), and expect to add 1~2 IND applications in 2021, which is expected to extend CDMO to gradually contribute new increments.</p><p><strong>Earnings Forecast and Investment Advice:</strong>The bank estimates that the company's revenue from 2021 to 2023 will be 9.36, 13.84 and 19.4 billion yuan, representing a year-on-year increase of 66.7%, 47.9% and 40.2%, and the net profit attributable to the parent will be 2.82, 4.17 and 5.88 billion yuan, representing a year-on-year increase of 67.1%, 47.6% and 41.2%, corresponding to EPS of 0.67, 0.98 and 1.39 yuan.</p><p><strong>Risk warning events:</strong>The public information used in the research report may be subject to the risk of information lag or updating in a timely manner, proposed acquisition<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>The risks of the progress of China's biologics production base project being less than expected, the investment in biologics research and development being less than expected, and the risk of loss of core technical personnel.</p><p></body></html></p>\n<div class=\"bt-text\">\n\n\n<p> source：<a href=\"http://www.zhitongcaijing.com/content/detail/543594.html\">智通财经</a></p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","relate_stocks":{"600918":"中泰证券","02269":"药明生物"},"source_url":"http://www.zhitongcaijing.com/content/detail/543594.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162031026","content_text":"智通财经APP获悉，中泰证券发布研究报告称，维持药明生物(02269)“买入”评级，认为公司是全球生物药外包服务行业稀缺标的，所处行业高景气、公司优势凸显，后续随着现有项目进入商业化，以及XDC、疫苗、双抗等平台加速兑现，长期空间广阔，未来可期。事件：公司发布2021年上半年业绩，期内实现营业收入44.1亿元，同比增长126.7%;归母净利润18.4亿元，同比增长150.3%;经调整归母净利润17.7亿元，同比增长163%。中泰证券主要观点如下：业绩超预期，归母净利润高于业绩预告。前次业绩预告2021H1归母净利润同比增长135%，实际增长150.3%，高于预期。该行认为主要源于：1)临床后期及商业化项目快速放量，其中临床阶段收入19.4亿元(同比+109.2%)，商业化阶段收入8.89亿(+2923.5%);2)海外疫情常态化后需求的快速恢复，2021H1北美收入21.9亿元(同比+149.3%)，欧洲收入9.9亿元(同比+706.8%);3)管理能力持续优化，运营效率持续提升，2021H1毛利率约为52.1%(+11.6pp)，净利率约为41.8%(+3.9pp)，期间费用率约12.4%(-8.2pp);4)去年基数低：去年上半年因疫情扰动导致整体基数较低，2020H1归母7.4亿(+63.6%)，但对比2019H1归母净利润，公司2019H1-2021H1CAGR约102.3%，增长迅猛。CMO放量逻辑持续兑现，跟随并赢得分子策略进展顺利，有望带动整体业绩加速增长。公司秉承跟随及赢得分子策略，截止6月30日，上半年延伸27个项目(14个临床前至临床、2个III期至商业化)，外部引进20个临床项目(+400%，其中临床II期9个、临床III期4个)，新增79个项目，整体项目数达408个(较2020H1同比+42.7%)，其中临床前212个(+50.4%)、早期(I期、II期)项目数达160个(+28%)，III期项目达32个(+68.4%)，商业化项目4个(新增三个)。此外，源于项目数不断快速增长，公司在手订单持续高增，预计未来三年能够完成订单总额达22.5亿美元(+143.1%)，未完成订单总额约124.6亿美元(+31.7%)，其中未完成服务订单72.3亿美元(+25.2%)。该行预计2021年将有7个商业化项目落地，有望推动CDMO板块新一轮放量，带动整体业绩提速增长。先进的XDC、疫苗、双抗平台带来增长新动能。XDC：公司XDC药物研发平台凭借WuXiDAR4技术优势承接48个ADC项目(+60%)，已有15个CDMO项目正在进行，商业化放量可期;WuxiVaccine：9个疫苗订单正在执行(同比增长8个)，在手订单提升至33亿美元，药明海德预计2022年投入运营，有望持续带来业绩增量。双抗：WuxiBody™承接31个项目(+19.2%)，预计2021年新增1~2个IND申请，有望延伸CDMO逐步贡献新增量。盈利预测与投资建议：该行预计2021-2023年公司收入93.6、138.4和194亿元，同比增长66.7%、47.9%、40.2%，归母净利润28.2、41.7和58.8亿元，同比增长67.1%、47.6%、41.2%，对应EPS为0.67、0.98、1.39元。风险提示事件：研究报告使用的公开资料可能存在信息滞后或更新不及时的风险、拟收购辉瑞中国生物药生产基地项目进展不及预期风险、生物药研发投入不及预期、核心技术人员流失的风险。","news_type":1,"symbols_score_info":{"600918":1,"02269":1}},"isVote":1,"tweetType":1,"viewCount":3400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}